New Techniques for the Qualitative and Quantitative Measurement of Naturally-Ocurring Gonadotropin-Releasing Hormone Analogues by Mass Spectrometry by Myers, Tanya R.
Georgia State University
ScholarWorks @ Georgia State University
Chemistry Dissertations Department of Chemistry
5-3-2007
New Techniques for the Qualitative and
Quantitative Measurement of Naturally-Ocurring
Gonadotropin-Releasing Hormone Analogues by
Mass Spectrometry
Tanya R. Myers
Follow this and additional works at: https://scholarworks.gsu.edu/chemistry_diss
Part of the Chemistry Commons
This Dissertation is brought to you for free and open access by the Department of Chemistry at ScholarWorks @ Georgia State University. It has been
accepted for inclusion in Chemistry Dissertations by an authorized administrator of ScholarWorks @ Georgia State University. For more information,
please contact scholarworks@gsu.edu.
Recommended Citation
Myers, Tanya R., "New Techniques for the Qualitative and Quantitative Measurement of Naturally-Ocurring Gonadotropin-Releasing
Hormone Analogues by Mass Spectrometry." Dissertation, Georgia State University, 2007.
https://scholarworks.gsu.edu/chemistry_diss/12
NEW TECHNIQUES FOR THE QUALITATIVE AND QUANTITATIVE  
 
MEASUREMENT OF NATURALLY-OCCURRING GONADOTROPIN-RELEASING  
 
HORMONE ANALOGUES BY MASS SPECTROMETRY    
 
by 
 
TANYA R. MYERS 
 
Under the Direction of Gabor Patonay 
 
ABSTRACT 
 
 
GnRH peptides have been discovered in a wide variety of vertebrate and 
invertebrate organisms, and work is ongoing to characterize additional unique isoforms. 
This dissertation describes the investigation of reversed-phase chromatographic and mass 
spectrometric behavior of GnRH peptides, the development and application of an LC-
MS/MS method for qualitative identification of GnRH peptides, and the comprehensive 
validation of an LC-MS/MS method for simultaneous, quantitative measurement of 
hydroxyproline9GnRH (Hyp9GnRH) and mammalian GnRH (mGnRH) in rat brain 
tissues.  
Chromatographic and mass spectrometric behavior of GnRH isoforms was 
characterized for six GnRH model peptides. Using reversed-phase high performance 
liquid chromatography (HPLC), nearly complete separation of the model GnRH peptides 
was achieved. Evaluation of electrospray source conditions indicated that certain 
parameters can be adjusted to affect the abundance of selected charge states and improve 
response. 
 Using the conditions found to be optimal for GnRH peptides in general, a method 
was developed to facilitate characterization of novel GnRH isoforms or confirm the 
identity of known isoforms. Fragmentation patterns for six model GnRH isoforms were 
examined to determine what portion of the primary sequence could be elucidated by de 
novo sequencing, and a simple solid phase extraction protocol was developed to isolate 
the model GnRH compounds from tissue samples. Application of the method to rat brain 
samples resulted in successful isolation and structural confirmation of 
hydroxyproline9GnRH and mammalian GnRH.  
A quantitative method for the determination of concentrations of 
hydroxyproline9GnRH and mammalian GnRH in rat brain tissue was developed and 
rigorously validated. Guinea pig brains were found to be a suitable substitute matrix for 
rat brains, and accuracy and precision were determined after four validation runs. 
Stability of both peptides in samples over long-term storage and under experimental 
conditions were evaluated, and the LC-MS/MS method was compared to an enzyme-
linked immunoassay. Thirty-one brains from Sprague-Dawley rats were analyzed using 
the LC-MS/MS procedure and compared to published results for Hyp9GnRH and 
mGnRH. 
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1CHAPTER 1: INTRODUCTION 
 
1.1 Overview 
Gonadotropin-releasing hormone (GnRH) is a critical neurohormone in the 
reproductive cycle of vertebrate species. In mammals, pulsatile release of the GnRH 
peptide from the hypothalamus stimulates the production of the gonadotropins FSH 
(follicle stimulating hormone) and LH (luteinizing hormone). These gonadotropins are 
released into systemic circulation for transport to the gonads, where they regulate 
gametogenesis and steroidogenesis. In addition to its critical role in reproduction, GnRH 
is thought to have functions beyond that of a neurotransmitter in vertebrates and has been 
found in tissues other than brain or pituitary (1). Fourteen GnRH isoforms have been 
identified thus far in vertebrates (2). 
Studies of GnRH in invertebrates have thus far been limited to protochordates, in 
which ten distinct forms have been identified (3-5). GnRH peptides are believed to have 
reproductive functions in invertebrates, although their role in regards to reproduction is 
less well understood as compared to that in vertebrates. Several studies have found 
hormonal action, while others have proposed pheromonal activity (5-7). Potential unique 
GnRH forms have been isolated in a number of other organisms including coral, 
freshwater snails, marine worms and sea slugs although the structures of these forms have 
not been determined (8-11). 
The forms of GnRH which have been identified in vertebrates and invertebrates 
are listed in Table 1.1. With the exception of mammalian GnRH, which was first isolated 
from pig and sheep and retains a more generic name, individual forms are listed by the 
organism in which they were first discovered. Older studies may use the name luteinizing 
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hormone-releasing hormone (LHRH), a more specific name originating prior to the 
discovery that GnRH also mediates release of FSH. 
 
Table 1.1. Amino acid sequences of naturally-occurring GnRH forms 
GnRH Amino Acid Sequence Ref. 
Vertebrate   
Catfish pGlu-His-Trp-Ser-His-Gly-Leu-Asn-Pro-Gly-NH2 (12) 
Chicken I pGlu-His-Trp-Ser-Tyr-Gly-Leu-Gln-Pro-Gly-NH2 (13, 14) 
Chicken II pGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH2 (15) 
Dogfish pGlu-His-Trp-Ser-His-Gly-Trp-Leu-Pro-Gly-NH2 (16) 
Guinea Pig pGlu-Tyr-Trp-Ser-Tyr-Gly-Val-Arg-Pro-Gly-NH2 (17) 
Herring pGlu-His-Trp-Ser-His-Gly-Leu-Ser-Pro-Gly-NH2 (18) 
Mammalian pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 (19, 20) 
Lamprey I* pGlu-His-Tyr-Ser-Leu-Glu-Trp-Lys-Pro-Gly-NH2 (21) 
Lamprey III pGlu-His-Trp-Ser-His-Asp-Trp-Lys-Pro-Gly-NH2 (22) 
Pejerrey** pGlu-His-Trp-Ser-Phe-Gly-Leu-Ser-Pro-Gly-NH2 (23) 
Rana pGlu-His-Trp-Ser-Tyr-Gly-Leu-Trp-Pro-Gly-NH2 (24) 
Salmon pGlu-His-Trp-Ser-Tyr-Gly-Trp-Leu-Pro-Gly-NH2 (25) 
Seabream pGlu-His-Trp-Ser-Tyr-Gly-Leu-Ser-Pro-Gly-NH2 (26) 
Whitefish pGlu-His-Trp-Ser-Tyr-Gly-Met-Asn-Pro-Gly-NH2 (27) 
Invertebrate   
Octopus pGlu-Asn-Tyr-His-Phe-Ser-Asn-Gly-Trp-His-Pro-Gly-NH2 (4) 
Tunicate I pGlu-His-Trp-Ser-Asp-Tyr-Phe-Lys-Pro-Gly-NH2 (3) 
Tunicate II pGlu-His-Trp-Ser-Leu-Cys-His-Ala-Pro-Gly-NH2 (3) 
Tunicate III pGlu-His-Trp-Ser-Tyr-Glu-Phe-Met-Pro-Gly-NH2 (5) 
Tunicate IV pGlu-His-Trp-Ser-Asn-Gln-Leu-Thr-Pro-Gly-NH2 (5) 
Tunicate V pGlu-His-Trp-Ser-Tyr-Glu-Tyr-Met-Pro-Gly-NH2 (5) 
Tunicate VI pGlu-His-Trp-Ser-Lys-Gly-Tyr-Ser-Pro-Gly-NH2 (5) 
Tunicate VII pGlu-His-Trp-Ser-Tyr-Ala-Leu-Ser-Pro-Gly-NH2 (5) 
Tunicate VIII pGlu-His-Trp-Ser-Leu-Ala-Leu-Ser-Pro-Gly-NH2 (5) 
Tunicate IX pGlu-His-Trp-Ser-Asn-Lys-Leu-Ala-Pro-Gly-NH2 (5) 
  *Lamprey II has not yet been fully characterized, and is therefore not included in the table. 
**Also referred to as Medaka. 
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Due to the critical function of GnRH in reproductive processes, the multiplicity of 
forms, the presence of certain isoforms in many diverse species (some of which are so-
called ancient forms), and the presence of this neuropeptide in vertebrates and 
invertebrates, interest in comparative studies of the GnRH family has grown considerably 
over the past 30 years. Such investigations of GnRH structures provide information about 
the evolution of the GnRH molecule and the evolution of reproductive systems. 
1.2 Peptide Structure 
All vertebrate forms of GnRH are decapeptides, as are all but one of the forms 
identified in invertebrates. Specific residues in the primary structures of the peptides are 
highly conserved, including the pyroglutamic acid N-terminus, the Ser4 residue (Ser6 in 
octopus GnRH), the Pro9 residue (Pro11 in octopus GnRH) and the amidated glycine C-
terminus. The His2 residue and the Trp3 residue are nearly conserved in that variations are 
observed in only a few organisms. 
The conservation of certain residues within the GnRH structure suggests that 
these residues may be important for conformation and activity of the peptide. A review of 
the effect of amino acid substitutions on GnRH activity suggests the following 
generalizations: 1) residues of the C-terminus (Pro-Gly-NH2) are important for binding to 
the GnRH receptor, 2) residues of the N-terminus (pGlu-His-Trp-Ser) play an important 
role in binding to and activation of the GnRH receptor, 3) His2 and Trp3 are probably 
involved and pGlu1 may be involved in receptor activation, 4) residues in the  central 
domain (residues 5 - 8), where more heterogeneity of amino acids is observed, are less 
critical although Arg8 appears critical for high-affinity binding of mammalian GnRH to 
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the mammalian GnRH receptor in pituitary, and 5) Gly6 is critical for appropriate folding 
of the peptide, possibly due to its lack of chirality (28).  
1.3 Distribution Among Organisms 
Many of the isoforms of GnRH have been identified in multiple species. The most 
widely distributed isoform, chicken II GnRH has been found in over 90 different 
organisms and is thought to be one of the most ancient isoforms found to date (29). The 
mammalian and chicken I isoforms also have been found in a diversity of organisms from 
multiple taxonomic classes, and salmon GnRH appears to be widely distributed among 
the Osteichthyes class of fish (bony fish) (29). Other isoforms, such as octopus, rana, and 
whitefish GnRH have been found in their respective species only (4, 24, 27). 
Based on the reported distribution of GnRH peptides, it is believed that 
vertebrates express at least two isoforms. In humans, the mammalian and chicken II 
forms are present (30). Multiple fish species have three forms, and it has been proposed 
that rockfish may produce a fourth, as yet uncharacterized form (13, 31). The diversity 
across species has generated interest in GnRH as an indicator of the evolution of 
reproductive processes. In addition, the diversity within a single species has generated 
interest in linking particular functions to the presence and levels of the distinct forms. 
1.4 Isoforms of Interest 
Eight GnRH isoforms were of particular interest to the research described in this 
dissertation – chicken I GnRH (cGnRH-I), chicken II GnRH (cGnRH-II), guinea pig 
GnRH (gpGnRH), lamprey III GnRH (lGnRH-III), mammalian GnRH (mGnRH), 
hydroxyproline mammalian GnRH (Hyp9GnRH), salmon GnRH (sGnRH) and seabream 
GnRH (sbGnRH). Six of these isoforms (cGnRH-I, cGnRH-II, lGnRH-III, mGnRH, 
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sGnRH and sbGnRH) were selected as model peptides for purposes of method 
development. cGnRH-II and mGnRH were chosen due to their importance in mammalian 
reproductive processes and for their reported presence in rat brain tissue; lGnRH-III and 
sGnRH were of interest for having been proposed also as present in rat brain tissue (32), 
the investigation of which is further described in Chapter 3.  cGnRH-I and sbGnRH were 
added to the group of model isoforms for additional structural heterogeneity during 
methods development. Two additional isoforms, Hyp9GnRH and gpGnRH, became of 
interest during the conduct of the experiments supporting this dissertation, as described in 
Chapters 3 and 4. Further details regarding distribution among organisms, localization, 
and functionality of these eight isoforms are described below. 
Chicken I GnRH 
 While Chicken I GnRH (cGnRH-I) was the first isoform discovered in avian 
species, it has a more limited distribution among species than cGnRH-II and has been 
found only in avian and select reptilian species (29). This paucity suggests that cGnRH-I 
is a newer form than cGnRH-II. Functionally, cGnRH-I is critical to reproductive 
processes in birds and is localized in the hypothalamic region (33). The primary structure 
of the cGnRH-I isoform is shown in Figure 1.1. 
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Figure 1.1. Primary structure of cGnRH-I 
 
 
Chicken II GnRH 
Chicken II GnRH (cGnRH-II) is the most widely distributed GnRH isoform, 
having been found in numerous mammals, birds, reptiles, amphibians, bony fish and 
cartilaginous fish (29). The breadth of distribution of this GnRH form, found in 
representative species of all vertebrate classes except the Agnanthans (lamprey), suggests 
that it is an older form than mGnRH (1). While cGnRH-II triggers FSH and LH release in 
mammals, it is not as effective as mGnRH (15). The locale of cGnRH-II (primarily 
distributed in the midbrain) differs from that of mGnRH (primarily distributed in the 
hypothalamus) in a number of vertebrate species, leading to speculation that the function 
of the two isoforms differs and that cGnRH-II may act as a neurotransmitter of unknown 
function (34). Similar to mGnRH, evidence of cGnRH-II has also been found in tissues 
outside the brain (35). The primary structure of the cGnRH-II isoform is shown in Figure 
1.2. 
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Figure 1.2. Primary structure of cGnRH-II 
 
 
Guinea Pig GnRH 
 The occurrence of guinea pig GnRH (gpGnRH) appears to be limited to select 
species; to date, it has been isolated only in guinea pig and capybara (36). The primary 
structure of gpGnRH is shown in Figure 1.3. 
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Figure 1.3. Primary structure of gpGnRH 
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Lamprey III GnRH 
 Three distinct GnRH-like peptides have been isolated in lamprey brain, and 
primary sequences have been proposed for two of the three, lamprey I GnRH (lGnRH-I) 
and lamprey III GnRH (lGnRH-III); further, both lGnRH-I and lGnRH-III have been 
found in three families of lamprey (21, 22, 37). While a few studies have suggested that  
lGnRH-I or III are expressed in rat, human and sheep and may be an FSH-releasing agent 
(38-41), others have found no evidence for this isoform in mammalian species (32, 42). 
The third GnRH-like peptide, deemed lamprey II GnRH, has never been fully 
characterized. The primary structure of the lGnRH-III isoform is shown in Figure 1.4. 
 
 
 
N
H
H
N
N
H
H
N
N
H
H
N
N
H
H
N
O
O
O
O
O
O
O
N
O
H
N
O
NH2
O
OH
NH
N
HN
O
N
NH
O
OH
NH
NH2
 
Figure 1.4. Primary structure of lGnRH-III 
 
 
Mammalian GnRH and hydroxyproline mammalian GnRH 
Mammalian GnRH (mGnRH) was the first LH- and FSH-releasing peptide to be 
isolated and characterized, initially in pig followed shortly thereafter in sheep (19, 20). 
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The mammalian isoform was thought to be unique until other homologous isoforms were 
discovered. mGnRH has subsequently been found in a wide variety of mammalian 
organisms (human, monkey, rodent) as well as bony fish and amphibians (29).  
The mGnRH peptide is released from the hypothalamus and is transported to the 
pituitary, where gonadotropin receptors release FSH and LH (34). Evidence for the 
presence of mGnRH has also been found in extra-hypothalamic tissues, including 
mammary gland, prostate, pancreatic, and placental tissue (35). A post-translationally 
modified form of mGnRH has been isolated and identified in human, sheep, rodent and 
frog hypothalamus; this modified form is distinguished from mGnRH by a hydroxylated-
proline in position 9 and is commonly referred to as hydroxyproline9 GnRH or 
Hyp9GnRH (32, 43). The primary structures of the mGnRH and Hyp9GnRH isoforms are 
shown in Figures 1.5 and 1.6, respectively. 
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Figure 1.5. Primary structure of mGnRH 
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Figure 1.6. Primary structure of Hyp9GnRH 
 
 
Salmon GnRH 
To date, salmon GnRH (sGnRH) has been found exclusively in bony fish, usually 
coexistent with at least one other isoform. In some species, sGnRH coordinates release of 
gonadotropins (analogous to mGnRH in mammals) while in other species, a different 
form of GnRH is responsible for this activity and the exact function of sGnRH is unclear; 
thus, the function of sGnRH in these fish is apparently complex and dependent upon 
location within the brain (29). The primary structure of the sGnRH isoform is shown in 
Figure 1.7. 
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Figure 1.7. Primary structure of sGnRH 
 
 
Seabream GnRH 
Seabream GnRH (sbGnRH) has been isolated solely in bony fish, in combination 
with sGnRH and cGnRH-II (26, 44, 45). When these three isoforms are found together, 
sbGnRH is the form isolated in the pituitary and is presumed to be the GnRH-releasing 
form (45-48). The primary structure of the sbGnRH isoform is shown in Figure 1.8. 
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Figure 1.8. Primary structure of sbGnRH 
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1.5 Nomenclature 
The original nomenclature applied to GnRH is somewhat ineffective in that a 
particular isoform can be found in many organisms. Several alternative naming strategies 
have been proposed in an effort to make the nomenclature more meaningful. One 
proposal suggests that isoforms should be referred to based on their homology to 
mammalian GnRH and that GnRH genes may be divided into one of three types, based 
on location of expression, function and molecular phylogenetic analysis (49). This 
scheme would redefine chicken II GnRH as {His5Trp7Tyr8}GnRH, indicating which 
positions are substituted relative to mammalian GnRH, and would define genes as 
GnRH-I if hypothalamic in origin, GnRH-II if mesencephalic (midbrain), and GnRH-III 
if telencephalic (endbrain). A fourth type (GnRH-IV) has been suggested to include the 
lamprey forms of GnRH (50). The individual isoforms are sometimes referred to by type. 
In humans, GnRH-I is the mammalian isoform based on its hypothalamic location, and 
GnRH-II is the chicken II isoform based on its mesencephalic location. Another 
nomenclature, also based on location and function, divides GnRH isoforms into MB-
GnRH (midbrain location), VF-GNRH (hypophysiotropic function located ventral 
forebrain), and TN-GnRH (neuromodulatory function located in terminal nerve) (51). 
However, confusion can be introduced when dealing with multiple organisms because the 
same isoform may have a different type or classification depending upon the organism 
(salmon GnRH is classified as GnRH-I in salmon and as GnRH-III in seabream). 
Isoform names based on comparisons of homology to mammalian GnRH quickly 
become unwieldy when dealing with multiple isoforms. Likewise, naming the isoforms 
based on type can be confusing when dealing with more than one organism. In addition, 
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none of these naming conventions address the invertebrate isoforms of GnRH. Because 
this dissertation research is concerned with developing quantitative and qualitative liquid 
chromatography – tandem mass spectrometry (LC-MS/MS) methods that are applicable 
to multiple isoforms, irregardless of location or function, the original nomenclature 
(based on the organism in which the isoform was first discovered) will be used. 
1.6 Analytical Methodologies – Limitations and Areas for Improvement 
Current analytical methodologies for identification of GnRH isoforms are highly 
dependent upon knowledge of the isoforms that may be present in a particular sample, a 
requirement that is somewhat contrary to the analysis of unknown or novel forms. 
Additionally, current methods (both qualitative and quantitative) must be performed 
individually for each unique isoform, a limitation that increases the amount of sample 
required as well as the time required to complete analysis for all isoforms. Furthermore, 
these methods require lengthy preparative steps and separation procedures. 
The experiments described in this dissertation demonstrate that simultaneous 
separation and identification of GnRH isoforms can be achieved in samples prepared 
using a relatively simple homogenization and clean-up procedure followed by LC-
MS/MS analysis. In addition, this sample preparation procedure can be adapted to 
quantitative measurements of multiple isoforms in the same sample. These new strategies 
for qualitative and quantitative determinations of GnRH isoforms are applicable to 
countless forms of the peptide and provide a more efficient and faster approach to GnRH 
analysis than existing techniques, which are discussed in further detail below. 
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Current Qualitative Methods 
Traditional analytical methodologies for identification of novel forms of GnRH 
utilize multiple HPLC fractionation steps with detection of putative GnRH peptides via 
immunoassay techniques, followed by structural confirmation via amino acid sequencing 
and molecular weight confirmation via mass spectrometry (18, 23, 27). These techniques 
rely on the availability of an antiserum with a broad specificity such that it will bind to 
the unknown form of GnRH. In the case of octopus GnRH, which has a 12 amino acid 
structure novel to the GnRH family of peptides, a more complicated protocol was 
utilized. Coarse purification of octopus GnRH was accomplished by use of an octopus 
heart bioassay for identification of bioreactive fractions from HPLC fractionation; 
subsequently, an antiserum specific to octopus GnRH was developed and used to identify 
specific fractions of interest for sequencing after further purification (4). 
Because sequencing and mass spectrometric methods are performed only on the 
immunoreactive fractions, the methods described above may not detect novel forms of 
GnRH in cases where the antisera employed are not reactive to the unknown form. In 
addition, multiple fractionation procedures and associated analyses are laborious, and 
structural confirmation must be performed individually for each form of GnRH that is 
tentatively identified via immunoassay. Assays for known forms of GnRH can be 
accomplished using antisera with specificity for the isoforms of interest, thereby 
eliminating the need for sequence identification. However, the possibility for false 
positive results exists, and such false results may be responsible for conflicting results 
regarding the isoforms present in rat brains (32). 
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Molecular biological techniques have been applied also to identify potential new 
forms of GnRH. The structure of rana GnRH was determined by cloning cDNA encoding 
for a peptide varying from mGnRH by one amino acid; immunohistochemistry was then 
used to probe various tissues for expression of the new isoform (24). In addition, seven 
new isoforms of GnRH in tunicates were determined using in silico methods as well as 
cDNA cloning and immunohistochemistry (5). These methods are also laborious and 
should be considered indirect in that expression of the peptides is determined by 
immunological responses rather than by directly sequencing the peptide. 
 To date, no methodology has been reported that can provide simultaneous 
separation and sequence identification of multiple GnRH analogues. This ability to detect 
multiple forms would be of tremendous benefit for studies of novel GnRH isoforms as 
well as studies of known isoforms in previously uncharacterized organisms. Thus, one of 
the goals of this dissertation was to develop a broadly applicable LC-MS/MS method 
capable of chromatographic separation of multiple GnRH isoforms with concurrent 
production of mass spectra having sufficient quality to propose the identity of unknown 
and known GnRH isoforms; a secondary objective was that this novel methodology be 
more efficient and faster to employ than methods currently used to identify GnRH 
isoforms.  
Current Quantitative Methods 
The conventional method for quantitation of GnRH in biological samples involves 
extraction from the matrix followed by immunoassay detection. Concentrations of 
various isoforms of GnRH have been measured via lab-developed immunoassay methods 
in a variety of sample matrices including human plasma (mGnRH, detection limit 0.1 
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pg/mL) (52), rat plasma and brain (mGnRH, 0.7 pg/mL) (53), hagfish brain (total GnRH, 
9.8 pg/mL) (54), lamprey brain (lGnRH-I and lGnRH-III, 98 pg/mL) (55), seabream 
pituitaries (sbGnRH, 100 pg/mL; cGnRH-II, 140 pg/mL; sGnRH, 40 pg/mL) (56), sea 
bass brain and pituitary (sGnRH, 40 pg/mL) (57), salmon gonad, brain and pituitary 
(sGnRH, 136 pg/mL) (58), perfusate from cannulized Ewes (mGnRH, 19 pg/mL) (59), 
and perfusate from cannulized rhesus monkeys (mGnRH, 0.7 pg/mL) (60). Commercial 
kits are also available. Detection limits comparable to those achieved from lab-developed 
immunoassay methods have been reported for measurement of mGnRH in rat plasma (0.1 
pg/mL) and mGnRH in human plasma (16 pg/mL) (61, 62). 
Several non-immunoassay methods have been employed for the analysis of GnRH 
concentration in biological samples. A liquid chromatographic assay with UV detection 
and lower limits of quantitation of 1.25 µg/mL has been utilized for determination of 
mGnRH and degradant products in intestinal extracts from possum (63). A capillary 
electrophoresis assay (UV detection) with lower limits of quantitation of 0.05 mM (60 
ug/mL) and 0.06 mM (70 µg/mL) for mGnRH and sGnRH, respectively, has been used to 
assay incubations of GnRH in intestinal extracts from salmon (64).  
A unique hybrid immunoassay – CE/MS method has been employed to determine 
mGnRH concentrations in serum and urine (65). An affinity capillary CE column 
selectively isolated mGnRH for quantitation by UV detection, with collection of 
qualitative mass spectral information. Reported detection limits were 1 ng/mL in plasma. 
The popularity of immunoassay methods is most likely due to the sensitivity 
(picomolar concentrations) that can be achieved. However, these methods may suffer 
from lack of specificity depending upon the antibodies used, cross-reacting with other 
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GnRH isoforms or metabolic and degradation products of GnRH. Due to this concern, 
many methods employ lengthy cleanup and HPLC fractionation steps prior to 
immunoassay. In addition, comparisons across studies may be hampered by the 
differences in antibodies used. 
A method capable of providing sensitive and selective determination of GnRH 
concentrations in biological samples, with broad applicability to the array of GnRH 
peptides, would be a useful addition to the methods currently employed for GnRH 
quantitative analysis. Therefore, another goal of the research described in this dissertation 
was to develop an LC-MS/MS-based method for quantitation of single or multiple GnRH 
isoforms, again with a secondary objective that this method be more efficient and faster 
to employ than methods currently used to determine GnRH quantities. 
1.7 Scope and Goals of the Research Project 
The focus of the dissertation research is the application of mass spectrometric 
methods to analysis of naturally-occurring GnRH peptides in biological samples. The 
work is directed toward three areas: exploration of the chromatographic and mass 
spectrometric behavior of the peptides, development of a qualitative method 
simultaneously applicable to multiple GnRH analogues, and development of a 
quantitative strategy that can be applied to multiple GnRH analogues.  
These methods offer significant improvements to current techniques for multiple 
reasons. Qualitative determinations of multiple GnRH isoforms by LC-MS/MS methods 
can be made in one analysis without prior knowledge of which isoforms may be in the 
sample, and without the need to develop or purchase antibody or cDNA products 
pertinent to unknown forms. Since multiple isoforms can be assayed in a single run, the 
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sample burden posed by multi-step procedures is reduced. The qualitative LC-MS/MS 
methods described in this dissertation also provide immediate insight into post-
translational modifications of expressed peptides, as spectral information is readily 
available to compare to that of the unmodified isoform. Finally, the LC-MS/MS-based 
approach allows quantitative measurements of multiple GnRH isoforms in one analysis 
and without concerns regarding cross-reactivity of antibody products. Subsequent 
chapters of this dissertation describe the preliminary experiments that were used to 
inform development of the qualitative and quantitative methods, followed by discussion 
of the qualitative and quantitative methods and application to brain tissue samples 
obtained from rat. 
The initial experiments conducted to define chromatographic and mass 
spectrometric behavior are discussed in Chapter 2. Factors affecting chromatographic 
separation, including mobile phase composition and additives, reversed-phase column 
composition, and gradient profiles were investigated using cGnRH-I, cGnRH-II, lGnRH-
III, mGnRH, sGnRH and sbGnRH. The effect of solution composition and electrospray 
parameters on peptide charge states during the electrospray process was evaluated as 
well. Knowledge gained from this work was used to develop the instrumental methods 
applied in the qualitative and quantitative portions of the dissertation research. 
Chapter 3 describes the development of a qualitative method with broad 
applicability to multiple GnRH isoforms. MS/MS fragmentation patterns for six GnRH 
isoforms were examined in detail to determine whether common fragments or patterns 
are formed that may be helpful in identifying putative GnRH peptide spectra. The six 
model GnRH isoforms were used to prepared spike samples for development of an 
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appropriate clean-up method and application of the method to isolation and identification 
of mGnRH and Hyp9GnRH in rat brain is described. 
 In chapter 4, development of LC-MS/MS strategies for quantification of mGnRH 
and Hyp9GnRH in rat brains is described. Selection of an appropriate calibration 
preparation strategy, selection of the regression model, recovery of mGnRH and 
Hyp9GnRH after sample preparation, and stability of the analytes in samples under 
storage and experimental conditions are discussed. Figures of merit, such as accuracy and 
precision, are evaluated in addition to assay specificity and sensitivity. Comparison of 
sample analysis via the new LC-MS/MS method versus an existing immunoassay 
technique is included, and concentrations of mGnRH and Hyp9GnRH in male and female 
Sprague-Dawley rat brains, as determined by the LC-MS/MS assay, are presented. 
 The dissertation concludes with a discussion of the advantages and limitations of 
the new LC-MS/MS techniques in Chapter 5. 
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2CHAPTER 2: CHROMATOGRAPHIC AND MASS SPECTROMETRIC 
BEHAVIOR OF GnRH PEPTIDES 
 
2.1 Introduction 
With the realized success of genome-sequencing projects, interest has rapidly 
grown toward identifying the protein and peptide profiles in organisms and how these 
profiles vary with age, stress, disease-state, and other conditions. Broad-spectrum mass 
spectrometric methods are frequently applied for proteomics and peptidomics studies in 
which the goal is the identification of the entire array of proteins or peptides in a sample. 
However, these studies require generic approaches designed to prevent discrimination, as 
much as possible, against any of a myriad of proteins and are not well suited to 
experiments for more specific targets. 
Analytical methods developed for a particular protein/peptide or family of 
proteins/peptides can be optimized to enhance specificity and sensitivity, unlike methods 
intended for generalized applications. In this dissertation, reversed-phase HPLC and 
quadrupole ion trap mass spectrometry methods are explored for qualitative and 
quantitative determinations of GnRH peptides. Clearly, selection of stationary phase and 
choice of mobile phase components affect chromatographic resolution (1).  In addition, 
substantial enhancements in electrospray response have been observed for a variety of 
compounds when methanol was compared to acetonitrile as the organic component for 
reversed-phase chromatography (2, 3). Further, mass spectrometric settings have been 
shown to impact response dramatically in a mixture of five proteins with varying 
physicochemical properties (4).  
28 
 
 
No systematic evaluation of the parameters affecting chromatographic resolution 
and mass spectrometric response of GnRH isoforms has been reported. Thus, it is 
expected that an investigation of the chromatographic and mass spectrometric 
characteristics of GnRH peptides would be useful in optimization of qualitative LC-
MS/MS methods for GnRH isoforms and quantitative LC-MS/MS methods for specific 
GnRH isoforms. To this end, a variety of parameters were explored, including mobile 
phase composition, reversed-phase column composition, and effects of solution 
composition and electrospray parameters on signal intensity and peptide charge states. 
Six GnRH peptides (cGnRH-I, cGnRH-II, lGnRH-III, mGnRH, sGnRH and sbGnRH) 
were chosen to investigate the impact of structural differences. These preliminary 
experiments will be used to inform development of HPLC-MS/MS methods for the 
qualitative and quantitative determination of GnRH isoforms in biological samples. 
2.2 Structure of the Peptides 
While the GnRH isoforms described in Table 1.1 have significant homology, amino 
acid variations amongst the isoforms result in differences in hydrophobicity and 
ionization that affect chromatographic retention and charge state. These differences in 
amino acid groups enable chromatographic separation of the peptide isoforms and affect 
the distribution of charge states (both in solution and in the gaseous phase). Ionizable 
residues and their respective acid dissociation constants (presented as a range expected 
within the local environment of  peptide or protein) for the six representative isoforms are 
shown in Figure 2.1 (5). 
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Figure 2.1. GnRH isoforms and their ionizable residues 
 
 
 Of the 24 GnRH isoforms thus far identified (see Table 1.1), twelve have one 
basic amino acid residue, eleven have two, and one has three. Five of the isoforms have 
one acidic residue also. Because the terminal ends of the GnRH isoforms are consistent 
and are not expected to be significantly charged as a consequence of their modified 
structures, the acidic and basic side chains of the amino acids will determine the total 
charge state of each peptide at a given pH. Our selection of three isoforms with one basic 
residue (cGnRH-I, sGnRH, and sbGnRH), two isoforms with two basic residues 
(cGnRH-II and mGnRH) and one isoform containing three basic residues and one acidic 
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residue (lGnRH-III) was expected to be representative of the family of GnRH isoforms 
such that conditions amenable to these six peptides should be applicable to most GnRH 
isoforms. Four of these six isoforms (cGnRH-II, lGnRH-III, mGnRH and sGnRH) were 
also of specific interest to the characterization of GnRH isoforms in rat brains (6). 
 Our goal was to find a set of experimental conditions that would provide optimal 
chromatographic resolution and mass spectrometric response for cGnRH-I, cGnRH-II, 
lGnRH-III, mGnRH, sGnRH and sbGnRH. Chromatographic separation of the isoforms 
was desirable, especially for data dependent experiments in which the most abundant 
signals trigger MS/MS experiments as compounds elute from the chromatographic 
column. Because some of the peptides differ in structure only by a single amino acid, full 
chromatographic resolution may be challenging to achieve. Thus, it was important to 
investigate the effect of mobile phase components and column composition on 
chromatographic resolution. Also, optimization of the mass spectrometric response was 
critical because the concentrations of GnRH in extracted samples were expected to be 
low (fmol/brain). The electrospray parameters required for optimal response were 
expected to differ somewhat due to heterologous structures in this peptide family, and the 
differing number of ionizable amino acid residues was expected to present some 
challenges in terms of promoting a single charge state (rather than splitting response 
across multiple charge states). Finally, differing conditions may be optimal in regards to 
chromatographic resolution versus mass spectrometric response and require that some 
compromises be made to achieve a generic LC-MS/MS method suitable for as many 
GnRH isoforms as possible. 
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2.3 Experimental 
Chemicals  
Purified cGnRH-I, cGnRH-II, mGnRH, lGnRH-III, sGnRH and sbGnRH were 
obtained from BAChem (Torrance, CA, USA). Glacial acetic acid, formic acid (88%), 
trifluoracetic acid (TFA), ammonium acetate, ammonium formate, and ammonium 
hydroxide (28-30%) were purchased from J.T. Baker (Phillipsburg, NJ, USA). 
Heptafluorobutyric acid (HFBA) was purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Acetonitrile and methanol were purchased from Burdick & Jackson (Muskegon, 
MI, USA), and water was purchased from the same or supplied by an in-house Vantage 
reverse-osmosis system (US Filter, Colorado Springs, CO, USA). 
Infusion experiments 
Effect of varying pH 
Stock solutions were prepared by diluting the purified peptide in deoxygenated 
water to 100 ug/mL, after which solutions were frozen at -70°C until use. Aqueous 
solutions were prepared across a range of acidic pH values typical for reversed-phase 
chromatography and at one basic pH value (see Table 2.1 for preparation schemes). 
Solution pH was measured in the aqueous solutions (prior to addition of organic solvent) 
using a calibrated pH meter (Orion 420A, Boston, Massachusetts, USA). A dilution of 
each peptide to 1 ug/mL was prepared from stocks in 95:5 pH-adjusted 
solution:acetonitrile; this small percentage of organic (calculated as volume:volume) was 
necessary to obtain reasonable signal intensity from the electrospray source. 
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Table 2.1. Preparation of pH-adjusted solutions 
pH Buffer Component Acid/Base used for pH 
Adjustment 
2.7 None Formic Acid 
3.8 10 mM Ammonium Formate Formic Acid 
4.8 10 mM Ammonium Acetate Acetic Acid 
5.3 10 mM Ammonium Acetate Acetic Acid 
5.7 10 mM Ammonium Acetate Acetic Acid 
9.1 10 mM Ammonium Acetate Ammonium Hydroxide 
 
 
Effect of varying organic concentration 
Solutions of each peptide were prepared from stocks diluted to a final 
concentration of 1 µg/mL with varying percentages of acetonitrile or methanol, two 
organic solvents commonly used for reversed-phase chromatographic separations of 
proteins and peptides. Because acidic conditions are frequently used for HPLC-MS/MS 
analysis of proteins and peptides, the experiments were repeated at three acidic pH values 
(2.7, 3.8 and 4.8). 
Effect of varying source conditions 
The effect of varying source conditions was explored using the 1 ug/mL solutions 
of each peptide prepared in 0.1% formic acid (pH=2.7):acetonitrile 
(75:25, volume:volume). The following parameters were varied: capillary heater (175-
350ºC, 25º increments), capillary voltage (-16 to 132 V, 10V increments), tube lens 
voltage (-10 to 140V, 10V increments), sheath gas (50 – 100 units, 10 unit increments), 
and source voltage (0 – 8.0kV, 1kV increments). 
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Chromatographic experiments 
 Preliminary experiments indicated that nearly complete separation (cGnRH-I and 
sbGnRH coeluted) of the six GnRH isoforms could be achieved using a Phenomenex 
Luna C8(2) 50 x 1.0 mm column, 5 µ particle size (Torrance, CA, USA) and acidified 
mobile phase. To further characterize the chromatographic behavior of the six isoforms 
on this column, several commonly used mobile phase modifiers were investigated for 
differences in chromatographic separation (if any) and response. Formic and acetic acid 
solutions were prepared at 0.01%, 0.05%, 0.1% and 0.5% (prepared as % volume) in 
water and paired with the same concentration of acid in acetonitrile for gradient 
chromatography; in addition, 0.01% TFA, 0.005% HFBA and the combinations of 0.01% 
acetic acid with 0.001% HFBA and 0.01% acetic acid with 0.005% HFBA were 
explored. A gradient program increasing from 5% organic to 60% organic over 55 min 
was used to achieve separation, and 10 µL of a 100 pg/µL mix of the six GnRH peptides 
was injected on-column. Phenomenex Luna C18(2) and Luna phenylhexyl columns were 
also evaluated, both 50 x 1.0 mm, 5 µ particle size (Torrance, CA, USA). A Phenomenex 
Jupiter Proteo (C12) column, designed specifically for peptide separations, was included 
in these experiments as well; the 50 x 1.0 mm, 4 µ particle size dimensions were chosen 
to be as comparable as possible with the conventional C18 and phenylhexyl phases. 
Mass spectrometry 
All experiments were performed on a Finnigan LCQ Deca quadrupole ion trap 
mass spectrometer (San Jose, CA, USA) operated in positive electrospray mode. The 
electrospray source was fitted with a stainless steel needle. 
34 
 
 
For the infusion experiments, solutions were infused into the electrospray source 
from the on-board syringe pump via capillary tubing. The infusion rate was 20 µL/min 
for the experiments exploring the effect of varying pH and organic content and 100 
µL/min for the experiments exploring varying source conditions. Ten to twenty MS scans 
were captured and averaged, with the scanned mass range selected based on the 
anticipated charge states for each peptide. Unless otherwise noted above, electrospray 
source conditions were as follows: source voltage – 3.0 kV, sheath gas flow (nitrogen) – 
50 units, auxiliary gas flow – 0 units, capillary voltage – 36 to 46 V, and capillary 
temperature – 175°C. 
For the chromatography experiments, column effluent at 100 µL/min was directed 
into the electrospray source without splitting. The following source conditions were 
selected: source voltage – 3.0 kV, sheath gas flow (nitrogen) – 100 units, auxiliary gas 
flow – 0 units, capillary voltage – 46 V, and capillary temperature - 200°C.  
2.4 Results and Discussion 
Effect of pH on charge state and absolute signal intensity 
 Results from the infusion of GnRH peptide solutions prepared in solutions of 
different pH are shown in Figure 2.3 and 2.4, depicting relative intensity and absolute 
intensity of each charge state, respectively. 
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Figure 2.2.  Infusion of GnRH isoforms, 1 µg/mL, at 20 uL/min, with varying pH. 
Data derived from average of 20 MS scans. Relative intensity for MH+, MH2+2 and 
MH3+3 (lamprey only) is shown for a) cGnRH-I, b) cGnRH-II, c) lGnRH-III, d) 
mGnRH, e) sGnRH and f) sbGnRH. MH+ is designated +1 and MH2+2 is designated 
+2. 
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Figure 2.3.  Infusion of GnRH isoforms, 1 µg/mL, at 20 uL/min, with varying pH. 
Data derived from average of 20 MS scans. Absolute intensity for MH+, MH2+2 and 
MH3+3 (lamprey only) is shown for a) cGnRH-I, b) cGnRH-II, c) lGnRH-III, d) 
mGnRH, e) sGnRH and f) sbGnRH. MH+ is designated +1 and MH2+2 is designated 
+2. 
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The single and double charge states were observed for all isoforms, and for 
lGnRH-III, the triply-charged form was observed as well. For cGnRH-I, sGnRH and 
sbGnRH, the singly-charged state was the predominant state (greater than 90% of total 
signal for MH+ and MH2+2), irregardless of solution pH; the similar behavior of these 
peptides is logical in that all three of these GnRH isoforms have a basic histidine residue 
in position 2 and an acidic tyrosine residue in position 5. For cGnRH-II and mGnRH, the 
doubly-charged state was the more abundant state, influenced somewhat by pH; these 
GnRH isoforms both have two basic residues in addition to an acidic tyrosine residue. 
The doubly-charged state was the most abundant charge state for lGnRH-III as well, 
ranging from 81 – 86% of the total signal for MH+, MH2+2, and MH3+3. The triply-
charged form of lGnRH-III was observed predominantly at the most acidic pH with 
signal intensity for this form dropping to less than 0.5% of the total signal at pH=3.7 and 
above. The singly-charged state of lGnRH-III ranged from 11% at pH=2.7 to 19% at 
pH=9.1. The primary structure for lGnRH-III includes four ionizable residues: two basic 
histidine residues at positions 2 and 5, an aspartic acid residue at position 6, and a basic 
lysine residue at position 8.  
The maximum charge observed for each peptide under the electrospray conditions 
employed in this experiment correlates to the maximum charge state expected based on 
solution chemistry (under moderately acidic conditions, +1 for cGnRH-I, sGnRH and 
sbGnRH; +2 for cGnRH-II and mGnRH; +3 for lGnRH-III). However, the maximum 
charge state observed did not always trend with pH as might be expected based on 
solution chemistry; this was especially apparent at pH = 9.1. These observations suggest 
that the electrospray process and reactions after transfer of the ions to gas phase are also 
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important determinants of charge state for the GnRH peptides, a phenomenon that has 
been observed for other peptides and proteins (7, 8). The absolute signal intensity for all 
of the charge states was greatest at pH=2.7, probably due to acid-enhanced charge 
separation during the electrospray process (9). 
Effect of organic composition on charge state and absolute signal intensity 
 Results from the infusion of GnRH peptide solutions prepared at varying 
concentrations of acetonitrile or methanol are shown in Figures 2.4 and 2.5. In most 
cases, increasing percentages of organic solvent resulted in increases in signal intensity 
irrespective of charge state. This result is consistent with previous observations that 
increasing percentages of organic solvent can stabilize the electrospray current and 
enhance response, probably due to reduced droplet surface tension and enhanced 
desolvation at higher concentrations of organic (9). Notable exceptions to this 
observation were cGnRH-I, sGnRH and sbGnRH, for which the MH+ signal diminished 
at higher percentages of acetonitrile at pH=2.7. Irregardless of whether the solutions were 
prepared with acetonitrile or methanol, electrospray response was enhanced at lower pH. 
39 
 
 
 
a)      b) 
0.0E+00
2.0E+06
4.0E+06
6.0E+06
8.0E+06
1.0E+07
1.2E+07
1.4E+07
1.6E+07
1.8E+07
0 10 20 30 40 50
%ACN
Ab
so
lu
te
 In
te
ns
ity pH=2.7, +1
pH=2.7, +2
pH=3.8, +1
pH=3.8, +2
pH=4.8, +1
pH=4.8, +2
0.0E+00
2.0E+06
4.0E+06
6.0E+06
8.0E+06
1.0E+07
1.2E+07
1.4E+07
1.6E+07
1.8E+07
2.0E+07
0 10 20 30 40 50
%ACN
A
bs
ol
ut
e 
In
te
ns
ity pH=2.7, +1
pH=2.7, +2
pH=3.8, +1
pH=3.8, +2
pH=4.8, +1
pH=4.8, +2
 
 
c)      d) 
0.0E+00
2.0E+06
4.0E+06
6.0E+06
8.0E+06
1.0E+07
1.2E+07
0 10 20 30 40 50
%ACN
A
bs
ol
ut
e 
In
te
ns
ity
pH=2.7, +1
pH=2.7, +2
pH=2.7, +3
pH=3.8, +1
pH=3.8, +2
pH=4.8, +1
pH=4.8, +2
 
0.0E+00
2.0E+06
4.0E+06
6.0E+06
8.0E+06
1.0E+07
1.2E+07
1.4E+07
1.6E+07
1.8E+07
0 10 20 30 40 50
%ACN
A
bs
ol
ut
e 
In
te
ns
ity pH=2.7, +1
pH=2.7, +2
pH=3.8, +1
pH=3.8, +2
pH=4.8, +1
pH=4.8, +2
 
 
e)      f) 
0.0E+00
2.0E+06
4.0E+06
6.0E+06
8.0E+06
1.0E+07
1.2E+07
1.4E+07
1.6E+07
0 10 20 30 40 50
%ACN
A
bs
ol
ut
e 
In
te
ns
ity pH=2.7, +1
pH=2.7, +2
pH=3.8, +1
pH=3.8, +2
pH=4.8, +1
pH=4.8, +2
0.0E+00
1.0E+06
2.0E+06
3.0E+06
4.0E+06
5.0E+06
6.0E+06
7.0E+06
8.0E+06
0 10 20 30 40 50
%ACN
Ab
so
lu
te
 In
te
ns
ity pH=2.7, +1
pH=2.7, +2
pH=3.8, +1
pH=3.8, +2
pH=4.8, +1
pH=4.8, +2
 
 
 
Figure 2.4.  Infusion of GnRH isoforms, 1 µg/mL, at 20 uL/min, with varying 
concentrations of acetonitrile. Data derived from average of 20 MS scans. Absolute 
intensity for MH+, MH2+2, and MH3+3 is shown for a) cGnRH-I, b) cGnRH-II, c) 
lGnRH-III, d) mGnRH, e) sGnRH and f) sbGnRH. MH+ is designated +1, MH2+2 is 
designated +2, and MH3+3 is designated +3. 
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Figure 2.5. Infusion of GnRH isoforms, 1 µg/mL, at 20 uL/min, with varying 
concentrations of methanol. Data derived from average of 20 MS scans. Absolute 
intensity for MH+, MH2+2, and MH3+3 is shown for a) cGnRH-I, b) cGnRH-II, c) 
lGnRH-III, d) mGnRH, e) sGnRH and f) sbGnRH. MH+ is designated +1, MH2+2 is 
designated +2, and MH3+3 is designated +3. 
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In general, acetonitrile enhanced signal intensity for the primary charge states of 
all six GnRH isoforms compared to methanol. This finding is the converse of that 
obtained during analysis of a non-natural mGnRH analogue, goserelin, for which 
response was enhanced four to eight-fold with methanol as the organic component of the 
mobile phase as compared to acetonitrile (3). The chemical structures of mGnRH and 
goserelin are similar (the glycine residue in position 6 and the amidated glycine in 
position 10 are replaced with a tert-butylserine reside and a carbazamide terminus, 
respectively), so it is not clear whether structural differences in goserelin lead to 
enhanced electrospray response from solutions containing methanol. It may be that 
differences in electrospray sources influence which organic modifer is optimal (the 
goserelin study was conducted using a Micromass Platform 2 single quadrupole mass 
spectrometer). 
2.5 Effect of electrospray source conditions on charge state 
Results from varying capillary heater temperature while infusing 1 µg/mL GnRH 
peptide solutions prepared in 0.1% formic acid, pH=2.7:acetonitrile (75:25, 
volume:volume) are shown in Figures 2.6. Likewise, results from varying capillary 
voltage, tube lens voltage, sheath gas flow, and source voltage are shown in Figures 2.7, 
2.8  2.9,  and 2.10, respectively. 
Of the electrospray source parameters manipulated in these experiments, capillary 
heater temperature and source voltage had the most significant effect on response of the 
six GnRH isoforms. For isoforms in which the +2 charge state was the more prominent 
form at pH=2.7 (cGnRH-II, lGnRH-III, and mGnRH), increasing capillary temperatures  
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Figure 2.6.  Effect of capillary heater temperature upon response. Infusion of 1 
µg/mL GnRH isoforms, in 75:25 1% formic acid:acetonitrile, at 100 uL/min. Data 
derived from average of 10 MS scans. Sheath gas flow was set to 50 units, source 
voltage was set to 3 kV, capillary voltage was set to 46 V, and the tube lens voltage 
was set to 5V. Absolute intensity for MH+, MH2+2, and MH3+3 is shown for a) 
cGnRH-I, b) cGnRH-II, c) lGnRH-III, d) mGnRH, e) sGnRH and f) sbGnRH. MH+ 
is designated +1, MH2+2 is designated +2, and MH3+3 is designated +3. 
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Figure 2.7.  Effect of capillary voltage upon response. Infusion of 1 µg/mL GnRH 
isoforms, in 75:25 1% formic acid:acetonitrile, at 100 uL/min. Data derived from 
average of 10 MS scans. Sheath gas flow was set to 50 units, source voltage was set 
to 3 kV, capillary heater was set to 200 V, and the tube lens voltage was set to 5V. 
Absolute intensity for MH+, MH2+2, and MH3+3 is shown for a) cGnRH-I, b) cGnRH-
II, c) lGnRH-III, d) mGnRH, e) sGnRH and f) sbGnRH. MH+ is designated +1, 
MH2+2 is designated +2, and MH3+3 is designated +3. 
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Figure 2.8.  Effect of tube lens voltage upon response. Infusion of 1 µg/mL GnRH 
isoforms, in 75:25 1% formic acid:acetonitrile, at 100 uL/min. Data derived from 
average of 10 MS scans. Sheath gas flow was set to 50 units, source voltage was set 
to 3 kV, capillary heater was set to 200 V, and capillary voltage was set to 46V. 
Absolute intensity for MH+, MH2+2, and MH3+3 is shown for a) cGnRH-I, b) cGnRH-
II, c) lGnRH-III, d) mGnRH, e) sGnRH and f) sbGnRH. MH+ is designated +1, 
MH2+2 is designated +2, and MH3+3 is designated +3. 
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Figure 2.9.  Effect of sheath gas flow upon response (flow setting to arbitrary units). 
Infusion of 1 µg/mL GnRH isoforms, in 75:25 1% formic acid:acetonitrile, at 100 
uL/min. Data derived from average of 10 MS scans. Tube lens voltage was set to 5V, 
source voltage was set to 3 kV, capillary heater was set to 200 V, and capillary 
voltage was set to 46V. Absolute intensity for MH+, MH2+2, and MH3+3 is shown for 
a) cGnRH-I, b) cGnRH-II, c) lGnRH-III, d) mGnRH, e) sGnRH and f) sbGnRH. 
MH+ is designated +1, MH2+2 is designated +2, and MH3+3 is designated +3. 
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e)      f) 
 
 
Figure 2.10.  Effect of source voltage upon response. Infusion of 1 µg/mL GnRH 
isoforms, in 75:25 1% formic acid:acetonitrile, at 100 uL/min. Data derived from 
average of 10 MS scans. Sheath gas flow was set to 50 units, tube lens voltage was set 
to 5V, capillary heater was set to 200 V, and capillary voltage was set to 46V. 
Absolute intensity for MH+, MH2+2, and MH3+3 is shown for a) cGnRH-I, b) cGnRH-
II, c) lGnRH-III, d) mGnRH, e) sGnRH and f) sbGnRH. MH+ is designated +1, 
MH2+2 is designated +2, and MH3+3 is designated +3. 
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resulted in a diminished response for MH2+2 and an enhancement in MH+1 response. At 
even higher capillary temperatures, MH+1 response was diminished also. Similarly, the 
MH+1 response of cGnRH-I, sGnRH and sbGnRh, for which the +1 charge state was the 
more prominent form at pH=2.7, was diminished at the higher capillary temperatures.  
The effect of source voltage variation on response was similar for all charge states 
and all isoforms in that there seemed to be an optimal range of settings for GnRH 
peptides centered at approximately 4 V; lower and higher settings resulted in significantly 
diminished response. Capillary voltage, tube lens voltage, and sheath gas flow changes 
affected response to a lesser extent, depending upon the charge state and isoform. 
The effect of higher capillary temperatures may be explained by an apparent 
conversion of higher charge states to lower charge states and has been dubbed “charge 
stripping” by the manufacturer of the LCQ Deca instrument used to gather these data (10, 
11). This effect may be unique to the design of the electrospray source and particularly, 
the heated capillary tube used to transfer ions from the atmospheric pressure region to the 
vacuum region. Interestingly, the manufacturer also reports that this phenomenon can 
occur at higher settings of tube lens voltage as well. However, increasing the tube lens 
voltage during infusion of the six GnRH isoforms did not affect the response in a uniform 
manner that would be suggestive of charge stripping. These results highlight the 
importance of characterization of peptide behavior in a particular mass spectrometric 
system, particularly if optimal response for a particular charge state is desired. 
2.6 Effect of acid modifiers on chromatography 
Results from the reversed-phase gradient separation of cGnRH-I, cGnRH-II, 
lGnRH-III, mGnRH, sbGnRH, and sGnRH on a Luna C8(2), 50 x 1.0 mm column with 
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varying concentrations of acetic acid and formic acid are shown in Figures 2.11 and 2.12, 
respectively. Results obtained using TFA and HFBA as mobile phase modifiers are 
shown in Figure 2.13. 
The elution order of the six GnRH isoforms was similar for the mobile phases 
modified with acetic acid, formic acid, and TFA, with complete resolution of all the 
isoforms except cGnRH-I and sbGnRH. Retention of the GnRH isoforms on the C8 
stationary phase was enhanced in the formic acid-modified mobile phase as compared to 
that modified with acetic acid. This increased retention was somewhat surprising in that 
while both acids have weak ion pairing capacities, the uncharged portion of the acetic 
acid group (CH3CO-) would be expected to interact slightly more effectively than the 
uncharged portion of the formic acid group (HCO-) with the non-polar stationary phase.  
Of the acid modifiers explored, the best electrospray response was observed in 
mobile phases prepared with acetic acid. Increasing concentrations of the acid modifiers 
lowered electrospray response. As would be expected, response was lowered also in 
mobile phases prepared with the strong ion-pairing reagents TFA and HFBA.  
Peak broadening for lGnRH-III, mGnRH and cGnRH-II was observed in mobile 
phase modified with 0.01% acetic acid and for lGnRH-III in mobile phases modified with 
0.01% formic acid or with 0.01% acetic acid and 0.001% HFBA. This peak broadening is 
likely due to interactions of the peptides with active silanol groups which can be ionized 
under moderately acidic conditions (pH ≥ 3.5) and become available for secondary 
chromatographic interactions (12, 13). The lGnRH-III, mGnRH and cGnRH-II isoforms 
are predominantly in a +2 or +3 charge state at acidic pH, thereby increasing the potential  
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Figure 2.11.  Effect of varying concentrations of acetic acid in mobile phase, 
reversed-phase chromatography on Luna C8(2). Chromatograms are normalized to 
the most intense peak, with maximum intensity displayed in the right-hand corner. 
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Figure 2.12.  Effect of varying concentrations of formic acid in mobile phase, 
reversed-phase chromatography on Luna C8(2). Chromatograms are normalized to 
the most intense peak, with maximum intensity displayed in the right-hand corner. 
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Figure 2.13.  Effect of varying concentrations of TFA and HFBA in mobile phase, 
reversed-phase chromatography on Luna C8(2). Chromatograms are normalized to 
the most intense peak, with maximum intensity displayed in the right-hand corner. 
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ionized sites on these peptides for interaction with active silanol groups. Mobile phases 
modified with either HFBA alone or acetic acid-HFBA combinations displayed 
significantly different elution orders for the isoforms and shifted the retention times of 
lGnRH-III, mGnRH and cGnRH-II later relative to the times for cGnRH-I, sbGnRH and 
sGnRH. This result may be explained by the greater hydrophobicity of HFBA as an ion-
pairing reagent, with an increased impact on higher net-charge peptides that have 
multiple sites available for ion-pairing (13). 
2.7 Effect of column composition and organic modifier on chromatography 
Conventional C18 and phenylhexyl-based stationary phases as well as a C12 
column designed especially for peptide separations were evaluated to determine whether 
chromatographic separation achieved on the C8 column could be improved. Each column 
was evaluated with 0.01% acetic acid, 0.5% acetic acid, 0.01% formic acid and 0.01% 
acetic acid with 0.001% HFBA as the mobile phase modifiers. In all cases, mGnRH and 
cGnRH-II eluted in broad peaks and lGnRH-III was either broadened to the extent that it 
became indistinguishable from baseline or was not retained by the column. Comparison 
of separations using the C8, C18, phenylhexyl and Proteo (C12) column are shown in 
Figure 2.14, using 0.5% acetic acid. Conversations with the manufacturer of these 
reversed-phase chromatography columns indicated that the C18 and phenylhexyl 
columns can have enhanced silanol activity relative to the C8 column due to less 
successful endcapping of active silanols in the presence of bulkier ligand groups (C18 
and phenylhexyl) (14). None of the columns investigated offered an improvement in  
resolution of cGnRH-I and sbGnRH over that achieved on the C8 column. Given that 
nearly full resolution of the six GnRH isoforms was achieved on the C8 column and that  
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Figure 2.14.  Effect of varying column composition on separation of GnRH isoforms. 
Chromatograms are normalized to the most intense peak, with maximum intensity 
displayed in the right-hand corner. 
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evaluation of additional columns would be cost-prohibitive, it was determined that further 
evaluation of  column compositions would not be pursued. 
2.8 Discussion 
Development of combined reversed-phase HPLC and mass spectrometric methods 
requires balancing the best parameters for resolution and for electrospray response, as the 
conditions producing the desired chromatographic resolution may not produce the 
optimal electrospray response. Furthermore, the conditions best for one compound may 
not be best for another. For qualitative method development, resolution of the test GnRH 
compounds was desired (to facilitate data-dependent experiments during which the mass 
spectrometer triggers MS/MS experiments based on MS response as compounds elute 
from the HPLC system). Because biological samples are expected to contain low 
concentrations of GnRH peptides, it was important also to identify general conditions that 
would produce optimal electrospray response for the GnRH peptide family, using the six 
isoforms as model compounds. For development of a quantitative method for a particular 
isoform or isoform(s), chromatographic resolution may be modified from the conditions 
employed for qualitative analysis and electrospray parameters can be selected to fully 
optimize conditions to those particular isoforms. 
The results obtained from infusions of solutions containing cGnRH-I, cGnRH-II, 
lGnRH-III, mGnRH, sGnRH and sbGnRH at different pH indicate that increased 
electrospray response (irregardless of charge state) was obtained at the lowest pH 
evaluated, 2.7. This pH is fully compatible with reversed-phase chromatography of 
peptides, as interactions with non-endcapped silanol groups are minimized at pH below 3.  
Experiments with varying capillary heater temperature and source voltage settings 
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revealed optimal ranges for qualitative methods; however, other electrospray parameters 
had less consistent effects on response, although these could be optimized for a particular 
isoforms if desired. Infusions of the GnRH isoforms in solutions of varying organic 
content demonstrated that, in general, response was enhanced with higher concentrations 
of organic and at lower pH. While response in solutions containing acetonitrile tended to 
be somewhat higher than those containing methanol, the difference was not completely 
consistent among isoforms and charge states, and either solvent would be suitable as the 
organic modifier for mobile phase. 
To achieve optimal sensitivity, it would also be desirable to select conditions 
whereby one of the charge states is dominant so that the signal for a particular peptide is 
not distributed between several m/z ratios. For cGnRH-I, sGnRH, and sbGnRH, over 90% 
of the absolute signal existed in the +1 charge state, irregardless of pH. However, for 
cGnRH-II, lGnRH-III and mGnRH, the signal was split between several charge states at 
all pH evaluated. While the electrospray response for the +2 charge states of these 
peptides was higher, the actual sensitivity achieved in practice with biological samples 
may be better at the higher m/z associated with the +1 charge states. The capillary 
temperature setting appears to offer a mechanism by which the charge states produced 
during the electrospray process may be shifted toward the +1 charge state, especially for 
lGnRH-III and mGnRH. 
Some initial starting conditions for chromatographic separation had been 
identified via experimentation with a 50 x 1.0 mm C8(2) Luna reversed-phase 
chromatography column prior to the work described in this chapter; in general, these 
initial conditions proved to be a good starting point. Nearly complete resolution of the six 
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model isoforms was achieved on this column with mobile phases prepared using formic 
and acetic acid. While formic acid and acetic acid produced similar results in terms of 
chromatographic separation, the electrospray response was somewhat enhanced in 
separations using acetic acid. Changing to a peptide specialty (C12), C18, or phenylhexyl 
column composition produced degraded chromatographic resolution or resulted in 
broadened peaks as compared to the C8 column. Mobile phases prepared with TFA or 
HFBA, two ion-pairing reagents that are frequently used for peptide/protein reversed-
phase separations, resulted in an expected loss of sensitivity and offered no advantage in 
terms of the chromatographic separation. 
2.9 Conclusions 
We sought to systematically evaluate the LC-MS/MS conditions that would affect 
chromatographic resolution and mass spectrometric response in our laboratory. Results 
demonstrated that nearly complete separation of the six model GnRH isoforms could be 
achieved within a reasonable time frame (30 minutes) when using mobile phases 
modified with either acetic or formic acid on the C8(2) 50 x 1.0 mm column. While the 
electrospray parameters were optimized for and may be peculiar to an LCQ Deca 
quadrupole ion trap mass spectrometer, the results indicate that certain source conditions 
can significantly affect charge state as well as response. In particular, we found that 
capillary heater temperature and source voltage settings might be useful to select for a 
particular charge state or optimizing response. 
These findings were used to develop the qualitative method described in Chapter 
3, which presents a novel LC-MS/MS approach to GnRH characterization that is more 
efficient and consumes less tissue than traditional approaches and eliminates the need for 
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specific antibodies. This method can be used to confirm the presence of any of the 
twenty-four known isoforms or to search for unknown isoforms in samples which have 
not been fully characterized for their GnRH content. The chromatographic separation 
developed in this chapter was important for the data-dependent experiments described in 
Chapter 3, and the investigation of source conditions allowed the selection of settings for 
optimal response of the model isoforms (and presumably the family of GnRH peptides). 
Because the LC-MS/MS method relies on de novo sequencing techniques to provide 
strong evidence of primary structure, further characterization of the model isoforms in 
regards to MS/MS fragmentation is described in Chapter 3. 
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3CHAPTER 3: A NEW ELECTROSPRAY IONIZATION-QUADRUPOLE ION 
TRAP MASS SPECTROMETRY-BASED STRATEGY FOR THE 
QUALITATIVE DETERMINATION OF GnRH PEPTIDES 
 
(The experiments described in this chapter have been published in Myers, T.R. and 
Patonay, G., A new strategy utilizing electrospray ionization-quadrupole ion trap mass 
spectrometry for the qualitative determination of GnRH peptides. Journal of Mass 
Spectrometry 2006, 41, 950-959. Copyright John Wiley & Sons Limited. Reproduced 
with permission.) 
 
3.1 Introduction 
Gonadotropin-releasing hormone (GnRH) is a critical neurotransmitter in vertebrate 
species, acting to stimulate and release gonadotropins for regulation of reproductive 
activities. GnRH is now thought to have functions beyond that of a neurotransmitter in 
vertebrates and has been found in tissues other than brain or pituitary, including those 
from mammary gland tumors, pancreas, and placenta (1). While several forms of GnRH 
have been found in invertebrates, functionality in these species is less understood. 
Twenty-four naturally-occurring forms of GnRH have been identified (2). All 
forms identified from vertebrates are decapeptides, as are all but one of the forms 
identified in invertebrates. The primary structures of the peptides are highly conserved, 
and all have an N-terminal pyroglutamic acid and a C-terminal amidated glycine (see 
Table 3.1). Most isoforms have been found in multiple species. In addition, most 
vertebrates have been found to express at least two isoforms. This diversity across species 
has generated interest in GnRH as an indicator of the evolution of reproductive processes. 
In addition, the presence of multiple forms within a single species has generated interest 
in linking particular functions to the presence and levels of the distinct forms. 
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Table 3.1. Primary structure and expected (M+H)+ for known GnRH isoforms 
GnRH 
Isoform 
Amino Acid Sequence (M+H)+ 
Catfish pGlu-His-Trp-Ser-His-Gly-Leu-Asn-Pro-Gly-NH2 1114.5 
Chicken I pGlu-His-Trp-Ser-Tyr-Gly-Leu-Gln-Pro-Gly-NH2 1154.5 
Chicken II pGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH2 1236.5 
Dogfish pGlu-His-Trp-Ser-His-Gly-Trp-Leu-Pro-Gly-NH2 1186.6 
Guinea Pig pGlu-Tyr-Trp-Ser-Tyr-Gly-Val-Arg-Pro-Gly-NH2 1194.6 
Herring pGlu-His-Trp-Ser-His-Gly-Leu-Ser-Pro-Gly-NH2 1087.5 
Lamprey I pGlu-His-Tyr-Ser-Leu-Glu-Trp-Lys-Pro-Gly-NH2 1226.6 
Lamprey III pGlu-His-Trp-Ser-His-Asp-Trp-Lys-Pro-Gly-NH2 1259.6 
Mammalian pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 1182.6 
Octopus pGlu-Asn-Tyr-His-Phe-Ser-Asn-Gly-Trp-His-Pro-Gly-NH2 1425.6 
Pejerrey pGlu-His-Trp-Ser-Phe-Gly-Leu-Ser-Pro-Gly-NH2 1097.5 
Rana pGlu-His-Trp-Ser-Tyr-Gly-Leu-Trp-Pro-Gly-NH2 1212.6 
Salmon pGlu-His-Trp-Ser-Tyr-Gly-Trp-Leu-Pro-Gly-NH2 1212.6 
Seabream pGlu-His-Trp-Ser-Tyr-Gly-Leu-Ser-Pro-Gly-NH2 1113.5 
Tunicate I pGlu-His-Trp-Ser-Asp-Tyr-Phe-Lys-Pro-Gly-NH2 1246.6 
Tunicate II pGlu-His-Trp-Ser-Leu-Cys-His-Ala-Pro-Gly-NH2 1117.5 
Tunicate III pGlu-His-Trp-Ser-Tyr-Glu-Phe-Met-Pro-Gly-NH2 1263.5 
Tunicate IV pGlu-His-Trp-Ser-Asn-Gln-Leu-Thr-Pro-Gly-NH2 1149.5 
Tunicate V pGlu-His-Trp-Ser-Tyr-Glu-Tyr-Met-Pro-Gly-NH2 1279.5 
Tunicate VI pGlu-His-Trp-Ser-Lys-Gly-Tyr-Ser-Pro-Gly-NH2 1128.5 
Tunicate VII pGlu-His-Trp-Ser-Tyr-Ala-Leu-Ser-Pro-Gly-NH2 1127.5 
Tunicate VIII pGlu-His-Trp-Ser-Leu-Ala-Leu-Ser-Pro-Gly-NH2 1077.5 
Tunicate IX pGlu-His-Trp-Ser-Asn-Lys-Leu-Ala-Pro-Gly-NH2 1119.6 
Whitefish pGlu-His-Trp-Ser-Tyr-Gly-Met-Asn-Pro-Gly-NH2 1158.5 
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Traditional analytical methodologies for identification of GnRH typically involve 
multiple HPLC fractionation steps followed by detection via immunoassay techniques, 
with confirmation of molecular weight by mass spectrometry and of primary structure by  
amino acid sequencing (3-5). Because only immunoreactive fractions are investigated, 
traditional methods may not detect GnRH in cases where the antisera employed are not 
reactive to the unknown form. In addition, multiple fractionation procedures and 
associated analyses are laborious, and structural confirmation must be performed 
individually for each form of GnRH that is tentatively identified via immunoassay. More 
recently, molecular biological techniques (in silico methods or cloning of cDNA) have 
been used to identify novel forms of GnRH (6-8). These techniques are also laborious, 
and expression of a particular GnRH form as well as any post-translational modifications 
must be confirmed individually. 
In this study, we demonstrate that de novo sequencing from ESI-MS/MS spectra of 
intact GnRH peptides provides adequate sequence coverage for proposing or confirming 
primary structure. Using simple sample preparation techniques, we were able to isolate 
and identify the chicken I, chicken II, lamprey III, mammalian, salmon and seabream 
isoforms in a spiked control sample. In addition, we were able to isolate and identify the 
mammalian GnRH (mGnRH) isoform as well as a modified version, hydroxyproline9 
mammalian GnRH (Hyp9GnRH), in Sprague-Dawley rat brains. To our knowledge, no 
methodology has been shown to provide simultaneous separation and identification of 
multiple GnRH analogues. 
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3.2 EXPERIMENTAL 
Chemicals and Reagents 
Glacial acetic acid, trifluoroacetic acid (TFA) and formic acid (88%) were 
purchased from J.T. Baker (Phillipsburg, NJ, USA). Acetonitrile and methanol were 
purchased from Burdick & Jackson (Muskegon, MI, USA). Water was either purchased 
from Burdick & Jackson (Muskegon, MI, USA) or supplied by an in-house Vantage 
reverse-osmosis system (US Filter, Colorado Springs, CO, USA). Bond Elut C18 solid-
phase extraction cartridges (200 mg) were purchased from Varian (Palo Alto, CA, USA). 
Ultramark 1621 and l-methionyl-arginyl-phenylalanyl-alanine (MRFA) were 
purchased from ThermoFinnigan (San Jose, CA, USA). Caffeine was purchased in 
powder form from Sigma-Aldrich (St. Louis, MO, USA). Peptide standards (chicken I, 
chicken II, lamprey III, mammalian, salmon and seabream GnRH) were purchased from 
BAChem (Torrance, CA, USA). Hydroxyproline9 GnRH was purchased from California 
Peptide Research (Napa, CA, USA). 
Standard preparation 
Stock standards of each GnRH peptide were prepared at 100 µg mL-1 in 
deoxygenated H2O. Subsequent dilutions were made into 1% formic acid to minimize 
adsorption to tube and vial walls. 
Mass spectrometry 
HPLC separations were performed using a Hewlett-Packard 1100 series binary 
pump and autosampler with vacuum degasser (Palo Alto, CA, USA) connected to a 
Phenomenex Luna C8(2) 50 x 1.0 mm column, 5µ particle size (Torrance, CA, USA). 
Mobile phase A consisted of 0.5% (vol/vol) acetic acid in water and mobile phase B 
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consisted of 0.5% (vol/vol) acetic acid in acetonitrile. A gradient program increasing 
from 5% B to 60% B over 55 minutes was used to achieve separation of the GnRH 
peptides. Column effluent, at 100 µL min-1, was directed into the electrospray source of 
the mass spectrometer without splitting. 
All experiments were performed using a Finnigan LCQ Deca quadrupole ion trap 
mass spectrometer (San Jose, CA, USA) operated in positive electrospray mode. The 
electrospray source was fitted with a stainless steel needle. Calibration of the mass 
spectrometer was performed using a mixture of caffeine, MRFA, and Ultramark 1621 as 
recommended by the manufacturer. Optimization of source conditions was performed 
while infusing sample from a syringe pump into mobile phase flow at 100 µL min-1. 
Evaluation of MS/MS fragmentation patterns was performed while infusing 1 µg mL-1 
sample (in 25:75 acetonitrile:0.1% formic acid) into the source from a syringe pump at 10 
µL min-1. MS/MS spectra were acquired over a series of collision energies to determine 
optimum conditions for de novo sequencing. 
The following source settings were selected as optimal for GnRH peptides: sheath 
flow (Nitrogen) - 100 units, auxiliary flow - off, source voltage – 4.5 kV, capillary 
temperature – 250°C, and capillary voltage – 22.0 V. Automatic gain control (AGC) was 
set to on, with a full AGC target of 5000000. Microscans were set to 3, with an injection 
time of 50 msec. Data-dependent experiments were designed such that MS scans (m/z 
1000-1275) reaching a threshold of 50 x 104 counts triggered an MS2 scan (default setting 
m/z 100-1275) on the most intense ion from the MS scan. A default isolation width of m/z 
2.8 was selected, collision energy was set to either 30 or 35%, and the activation Q was 
set to 0.250 with an activation time of 30 msec. No inclusion or exclusion criteria were 
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set for the data-dependent experiments. Targeted product-ion analysis experiments were 
conducted on specific GnRH precursor ions, with collision energy set to 35%, a default 
isolation width of 2.5, an activation Q of 0.250, and an activation time of 30 msec. The 
volume of sample extract consumed was 50 µL for data-dependent experiments, and 25-
50 µL for product-ion analysis and SIM experiments. 
Extraction procedure 
Rat brains were homogenized in polypropylene test tubes with 2-3 mL acetonitrile 
using a Tissue-Tearor tissue homogenizer (Biospec Products, Bartlesville, OK, USA). A 
control was prepared by homogenizing a single rat brain, to which was added 50 ng each 
chicken I and II, lamprey III, mammalian, salmon and seabream GnRH. Acetonitrile was 
added to bring the total volume of solvent to 5 mL, after which tubes were vortexed and 
centrifuged at 2500 g, 4ºC for 30 minutes. The supernatant was evaporated under 
nitrogen at 60ºC and reconstituted in 3 mL of the loading solution, which consisted of 
water:acetic acid:TFA (96:3:1, volume/volume). 
Solid phase extraction (SPE) was used to isolate GnRH from the brain 
homogenate samples. The SPE cartridges were preconditioned with 3 mL methanol 
followed by 3 mL of the loading solution. The reconstituted supernatant was transferred 
to the cartridges, which were subsequently washed with 3 mL loading solution followed 
by 3 mL 70:30 loading solution:methanol. Samples were eluted with 3 mL 30:70 3% 
acetic acid:methanol, which was collected and evaporated under nitrogen at 60ºC. For 
experiments where brain extracts were combined, extracts were pooled into one extract as 
they neared dryness, with the final combined extract taken fully to dryness. Samples were 
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reconstituted in 200 µL 95:5 3% acetic acid:methanol, vortexed for 30 seconds and 
transferred to glass autosampler vials for analysis. 
Peptide confirmation with synthetic GnRH standards 
Aliquots of 50 µL were removed from the total reconstitution volume (200 µL) of a 
single brain extract and transferred to separate glass autosampler vials. A standard 
solution of 5 pg/uL Hyp9GnRH and 20 pg/uL mGnRH was prepared in 95:5 3% acetic 
acid:methanol, and 10 µL of this standard was transferred to one of the aliquots while 10 
µL of 95:5 3% acetic acid:methanol was added to the second aliquot. The total volume of 
both aliquots was analyzed in product-ion analysis experiments for m/z 1182 and 1198. 
3.3 RESULTS AND DISCUSSION 
Mass spectral data/fragmentation patterns 
Known GnRH peptides have certain similarities in primary structure. The proline 
residue, at one position removed from the C-terminal amidated glycine (see Table 3.1), is 
such a constant residue that is expected in new forms of GnRH. Proline residues can have 
significant implications for MS/MS fragmentation by promoting intense fragmentation on 
the N-terminal side of the proline residue (9-11). Selective production of a single 
prominent y or b ion could obscure the series of ions necessary to perform de novo 
sequencing of novel GnRH forms. To determine whether an adequate series of ions could 
be observed from fragmentation in the quadrupole ion trap, MS/MS fragmentation 
patterns were examined for chicken I and II, lamprey III, mammalian, salmon and 
seabream GnRH. 
Optimal % collision energies were selected as those which optimized 
fragmentation without a severe reduction in overall signal intensity. Fragmentation data  
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Figure 3.1.  ESI-MS/MS spectrum of singly-charged cGnRH-I, precursor ion at m/z 
1154.4, average of 10 scans.  
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Figure 3.2.  ESI-MS/MS spectrum of singly-charged cGnRH-II, precursor ion at m/z 
1236.4, average of 10 scans.  
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Figure 3.3.  ESI-MS/MS spectrum of singly-charged lGnRH-III, precursor ion at 
m/z 1259.5, average of 10 scans.  
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Figure 3.4.  ESI-MS/MS spectrum of singly-charged mGnRH, precursor ion at m/z 
1182.6, average of 10 scans.  
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Figure 3.5.  ESI-MS/MS spectrum of singly-charged sGnRH, precursor ion at m/z 
1212.4, average of 10 scans.  
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Figure 3.6.  ESI-MS/MS spectrum of singly-charged sbGnRH, precursor ion at m/z 
1113.4, average of 10 scans.  
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were collected for all charge states observed for the peptides. The MS/MS spectra for the 
singly-charged states are shown in Figures 3.1 through 3.6, and the fragment ions 
observed for each charge state are shown in Figure 3.7. Only a, b, and y fragment ions are 
indicated in Figures 3.1 through 3.7 as these are the most useful for de novo sequencing. 
The observed m/z is also indicated for fragments of special interest in identifying spectra 
from GnRH peptides. 
The spectra collected from singly-charged peptides contained predominantly a 
and b fragment ions with some y and internal cleavage fragment ions. The b8 ion was 
prominent in all cases, indicating that the proline residue does promote selective 
fragmentation N-terminal to position 9. While a full series of b ions was not observed, b3- 
b9 were detected in all cases; this series can be used to deduce the amino acid residues in 
positions 4-9. The amino acid residue in position 3 could be deduced by identification of 
the y8 fragment ion (also observed for all GnRH forms) and a priori knowledge of the 
amidated glycine at the C-terminus. Based on these experiments and assuming that the 
structural similarities on each terminus are consistent, most known forms of GnRH could 
be identified using MS/MS fragmentation experiments on a quadrupole ion trap. Octopus 
GnRH (with an unusual 12 residue length) was not investigated, but it seems likely that 
similar fragmentation patterns would be observed, yielding useful sequencing 
information and possibly sufficient data to propose a complete sequence. 
MS/MS spectra of the doubly-charged mammalian and lamprey III GnRH 
peptides contained useful b and y fragment series that could be used for sequencing as 
noted above for the singly-charged peptides. The spectra obtained from the doubly-
charged forms of chicken I, chicken II and seabream GnRH and the triply-charged  
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Figure 3.7.  a, b, and y fragment ions identified in ESI-MS/MS spectra for GnRH 
peptides, with optimal collision energy shown in parenthesis. (a) cGnRH-I, (b) 
cGnRH-II, (c) lGnRH-III, (d) mGnRH, (e) sGnRH and (f) sbGnRH.  
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lamprey GnRH contained shorter series of b and y fragment ions. In cases where 
insufficient data were obtained from the multiply-charged forms to deduce the complete 
GnRH structure, complementary information was observed that could be useful to 
support a proposed de novo sequence obtained from the singly-charged peptide. 
GnRH isolation and identification from Sprague-Dawley rat brains 
In data-dependent MS/MS scanning experiments, manual review of data to 
identify the peptide spectra of interest can be laborious without a strategy for selection of 
relevant data. The product-ion analysis data from the six model peptides and the 
analogous terminal structures of the known forms of GnRH can be used to predict 
features that are expected in MS/MS spectra of these peptides. A common pattern arises 
from the structural similarity observed through the fourth amino acid position on the N-
terminus for nearly all known forms. This similarity leads to a characteristic b4 and b4-
H2O fragment ions at m/z 522 and 504, respectively, which can be used as keystones to 
identify potential GnRH spectra. The structures of lamprey I and guinea pig GnRH 
suggest that additional forms may be discovered that contain substitutions in positions 2 
and 3, and in these cases, marker ions at m/z 522 and 504 are not expected. An additional 
indicator based on the separation of the b8 and b9 fragment ions by 97 m/z units may be 
useful and should be easily identifiable since the b8 fragment is one of the most 
predominant ions in the spectrum. This pattern would be expected for all forms of GnRH, 
except the unique octopus isoform for which the b10 and b11 fragment ions would be 
separated by 97 m/z units. 
Data-dependent scanning experiments were performed to examine a control 
sample which was spiked with 50 ng each chicken I and II, lamprey III, mammalian, 
76 
 
 
salmon and seabream GnRH. The mass range (m/z 1000-1275) was selected to 
encompass singly-charged peptides of known vertebrate GnRH isoforms; this range was 
chosen after exploratory experiments indicated that higher background levels at lower 
mass ranges would preclude sufficient sensitivity for detection of doubly- and triply-
charged GnRH peptides in data-dependent experiments. Strategies described above were 
used to review the spectra obtained, and each of the isoforms added to the control sample 
were detected by data-dependent scanning. The spectra obtained for each isoform are 
shown in Figures 3.8 through 3.13. Chromatographic separation of the GnRH isoforms in 
the control sample is shown in Figure 3.14. This proof-of-concept experiment confirmed 
the viability of the method at a level (approximately 40 pmoL) that would be expected 
from a small pool of rat brains, based on results reported for mGnRH in mature rat brains 
(12). 
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Figure 3.8.  ESI-MS/MS spectra of cGnRH-I extracted from Sprague-Dawley rat 
brain control samples, precursor ion at m/z 1154.4. Data acquired in data-dependent 
scan mode with %CE=30. Spectra are averaged across the peak of interest. 
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Figure 3.9.  ESI-MS/MS spectra of cGnRH-II extracted from Sprague-Dawley rat 
brain control samples, precursor ion at m/z 1236.4. Data acquired in data-
dependent scan mode with %CE=30. Spectra are averaged across the peak of 
interest. 
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Figure 3.10.  ESI-MS/MS spectra of lGnRH-III, extracted from Sprague-Dawley rat 
brain control samples, precursor ion at m/z 1259.5. Data acquired in data-
dependent scan mode with %CE=30. Spectra are averaged across the peak of 
interest. 
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Figure 3.11.  ESI-MS/MS spectra of mGnRH extracted from Sprague-Dawley rat 
brain control samples, precursor ion at m/z 1182.4. Data acquired in data-
dependent scan mode with %CE=35. Spectra are averaged across the peak of 
interest. 
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Figure 3.12.  ESI-MS/MS spectra of sGnRH extracted from Sprague-Dawley rat 
brain control samples, precursor ion at m/z 1212.6. Data acquired in data-
dependent scan mode with %CE=30. Spectra are averaged across the peak of 
interest. 
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Figure 3.13.  ESI-MS/MS spectra of sbGnRH extracted from Sprague-Dawley rat 
brain control samples, precursor ion at m/z 1113.4. Data acquired in data-
dependent scan mode with %CE=30. Spectra are averaged across the peak of 
interest. 
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Figure 3.14.  Reconstructed ion chromatogram of GnRH peptides extracted from 
Sprague-Dawley rat brain control samples. 
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When a pooled extract from 10 Sprague-Dawley rat brains was examined in data-
dependent experiments, putative peptides of MH+ at m/z 1182 and 1198 were detected. 
Spectra for both peptides are shown in Figure 3.15. No spectra were observed that would 
be indicative of chicken II, lamprey III, or salmon GnRH or any other novel forms of 
GnRH. The same experiment conducted on the extract from a single brain also produced 
spectra for a putative peptide at m/z 1182 but was unable to detect the putative peptide at 
m/z 1198. 
The averaged spectrum obtained for the putative peptide at m/z 1182 was 
consistent with spectra obtained for mGnRH in the infusion experiment and in the control 
sample. The b4-H2O (m/z 504) and b4 ions (m/z 522), useful for identifying spectra from 
potential GnRH isoforms, were readily apparent. The b8 ion was the most prominent ion, 
but no b9 ion was observed above baseline noise level. The retention time for the putative 
peptide at m/z 1182 was consistent with that obtained for mGnRH in the control sample. 
Comparison of the spectra for the two putative peptides at m/z 1182 and 1198 
suggested strong homology. An identical series of b3-b8 ions were observed, with the b8 
ion a prominent feature in the fragmentation pattern. An addition of +16 to the y8 ion was 
also observed, indicating structural modification to one of the two amino acids on the 
carboxy-terminus. The retention time for this peptide under reversed phase conditions 
was somewhat earlier than mGnRH, suggesting that the structure was slightly more polar 
than mGnRH. Taken together, these patterns suggest the Hyp9GnRH isoform; however, 
based on these results alone we could not eliminate the possibility of other structures, 
especially since hydroxyproline and leucine/isoleucine are isobaric amino acids. 
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Figure 3.15.  Combined extracts from 10 Sprague-Dawley rat brains, (a) putative 
mGnRH peptide, ESI-MS/MS at m/z 1182.5, %CE=35, average of 11 scans and (b) 
putative hydroxyproline GnRH peptide, ESI-MS/MS at m/z 1198.7, %CE=35, 
average of 3 scans. 
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In an attempt to obtain additional structural information from the pooled extract, 
product-ion analysis experiments were conducted for the putative peptides. These 
experiments were conducted for singly- and doubly-charged forms of the peptides. 
Spectra obtained from singly-charged peptides (m/z 1182 and 1198) did not contain any 
additional structural information beyond that obtained during data-dependent 
experiments. Spectra obtained from doubly-charged peptides (m/z 592 and 600) 
demonstrated a series of y-type ions from y2-y8, all of which showed an increase of +16 
for the proposed hydroxyproline9 isoform. MS3 scans on the y2 ion were dominated by 
y2-NH3 and an immonium ion for the amino acid in position 9 (m/z 70 for mGnRH and 
m/z 86 for the proposed hydroxyproline9 isoform). While this information did not identify 
the amino acid in position 9, it did allow assignment of the +16 shift to that position. MS2 
and MS3 spectra for both peptides are shown in Figure 3.16. 
A Hyp9GnRH peptide standard was obtained for confirmatory experiments. 
Fragmentation spectra of the precursor ion at m/z 1198 were evaluated for the standard (1 
ng injected on-column) using the same HPLC and product-ion analysis conditions as for 
the pooled extracts, with results indicating a similar retention time and fragmentation 
pattern as the putative peptide observed at m/z 1198. Comparison of two aliquots from a 
single rat brain extract, one fortified with 10 µL reconstitution solution and one fortified 
with 10 µL reconstitution solution containing 50 pg Hyp9GnRH and 200 pg mGnRH 
confirmed that the synthetic Hyp9GnRH and mGnRH standards coeluted with the 
putative peptides. Reconstructed ion chromatograms and spectra from this experiment are 
displayed in Figure 3.17. The spectra observed in the sample containing the synthetic 
peptides are consistent with those observed in the unadulterated sample. This experiment  
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       a)      b) 
 
      c)      d) 
 
 
Figure 3.16.  Combined extracts from 10 Sprague-Dawley rat brains, (a) product-
ion spectra of m/z 599.7, %CE=20, average of 10 scans, (b) product-ion spectra of 
m/z 599.7 →m/z 188.0, %CE=25, average of 22 scans, (c) product-ion spectra of m/z 
591.7, %CE=20, average of 11 scans and (d) product-ion spectra of m/z 591.7 → m/z 
171.9, %CE=25, average of 29 scans. 
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Figure 3.17.  Comparison between single Sprague-Dawley rat brain extract fortified 
with 10 µL reconstitution solution (shown in gray) or 10 µL same containing 50 pg 
Hyp9 GnRH and 200 pg mGnRH (shown in black). (a) reconstructed ion 
chromatogram of m/z 1198.4, (b) reconstructed ion chromatogram of m/z 1182.5, (c) 
product-ion spectrum of m/z 1198.4 and (d) product ion spectra of m/z 1182.5. 
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also allowed an approximation of Hyp9GnRH and mGnRH quantities in this rat brain 
tissue of 200 pg (200 fmol) and 1000 pg (1 pmol), respectively. 
Previous work has suggested the presence of chicken II (13), lamprey III (14), and 
salmon GnRH (15) isoforms in addition to Hyp9GnRH and mGnRH in the brains of rats 
(12, 16). To investigate whether these additional isoforms may have been missed by the 
data-dependent algorithm, a targeted SIM experiment for the expected precursor masses 
of these isoforms was conducted on the pooled extract. No peaks were observed at the 
expected retention times for chicken II, lamprey III, and salmon GnRH in the rat brains. 
The aforementioned studies utilized detection via antisera to the respective GnRH forms. 
Because these studies relied on the specificity of the antisera employed and did not 
include any structural identification of the peptides, it is possible that false positive 
responses were obtained for chicken II, lamprey III, and salmon GnRH. 
The techniques described here provide a methodology by which GnRH isoforms 
can be separated and identified by de novo sequencing, avoiding the specificity problems 
associated with immunoassay-related methods. Targeted product-ion analysis 
experiments can be easily designed for known forms of GnRH, while data-dependent 
experiments provide a means to detect novel forms of GnRH. Although we were 
successful using manual interpretation of the data, recognition of GnRH-related spectral 
features, such as the characteristic ions observed for b4 and b4-H2O and the difference in 
m/z between b8 and b9, could be facilitated by use of software algorithms (17, 18). The 
presence of structural isomers (leucine/isoleucine) or isobaric amino acids (glutamine and 
lysine, hydroxyproline and leucine/isoleucine) in the proposed peptide sequence may 
require the use of additional techniques. In this study, addition of a synthetic Hyp9GnRH 
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standard to an extracted sample was required to provide confirmation of the proposed 
peptide sequence.  
One of the main advantages of this methodology is that it can identify putative 
GnRH peptide structures from a smaller tissue sample than other reported methods. Ten 
brains were required to produce pooled extract with sufficient signal for data-dependent 
experiments, and a single rat brain was sufficient to conduct multiple experiments on 
known or suspected GnRH precursor ions. In contrast, 100-200 rat brains were reported 
consumed in an effort to fully characterize GnRH forms (12); while the total tissue 
consumed was not devoted solely to qualitative determinations, this work still required a 
substantial quantity of animals. Of course, the quantity of tissue (or other matrix) 
required will vary depending upon the organism under study. 
The detection limit for this method will vary depending upon whether product-ion 
analysis experiments are sufficient to characterize a sample for known GnRH peptides or 
whether data-dependent experiments are required to elucidate unknown GnRH variants. 
For product-ion analysis experiments, a practical limit of detection of 10 pg (10 fmol) for 
both Hyp9GnRH and mGnRH was estimated by determining the smallest volume of 
extract (single brain) capable of generating GnRH peaks with a signal-to-noise ratio 
greater than 3 and with reasonable mass spectral quality. The practical limit of detection 
for data-dependent experiments will vary considerably depending upon experimental 
setup and sample quality; in this case, 300-500 pg was sufficient to trigger MS/MS scans 
useful for sequence determination. While the detection limits of immunoassay methods 
for GnRH are typically on the order of pg/sample, this HPLC-MS/MS methodology 
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allows simultaneous detection and identification of multiple GnRH isoforms while 
collecting valuable structural information. 
3.4 CONCLUSIONS 
The experiments described in this chapter were focused on developing a 
generalized approach to the separation and identification of GnRH isoforms. The method 
utilized a simple solid-phase extraction followed by LC-MS/MS analysis to acquire 
sequence information about the peptides. The method also provides simultaneous 
detection of multiple isoforms, and does not require the lengthy multi-chromatographic 
fractionation typically used prior to traditional immunoassay measurements. Because 
immunoreactive detection is not used, the possibility that an isoform will be missed if it 
does not cross-react with the antibodies employed during purification is eliminated. Also, 
the LC-MS/MS approach does not require any prior knowledge of the expected isoforms 
aside from the expected homology in the GnRH family, although experiments can be 
tailored to detect specific isoforms. 
Given the strong interest in identifying the multiple forms of GnRH in a variety of 
organisms, less laborious qualitative approaches would be welcome. These results 
demonstrate that ESI-MS/MS techniques provide a simple approach to GnRH 
characterization that is rich in qualitative information. The fragmentation patterns 
obtained from product-ion analysis experiments with six model GnRH peptides contained 
sufficient sequencing information, when used in conjunction with knowledge about the 
conserved amino acid residues in GnRH peptides, to define the intact peptide structure. 
Data-dependent experiments followed by targeted product-ion analysis experiments were 
conducted on extracts from Sprague-Dawley rat brains, and mammalian GnRH and 
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hydroxyproline9 GnRH, a post-translationally modified form of mammalian GnRH, were 
identified. These results confirm the ability of a relatively simple extraction and ESI-
MS/MS experiment to isolate and identify GnRH peptides in biological samples. Using 
this methodology, we were able to determine GnRH identities using a minimal quantity 
of tissue. In addition, the technique should also be applicable as an indicator of the 
presence of novel GnRH forms and may assist in the identification of such forms. 
Targeted product-ion analysis experiments were conducted in the extract from a 
pool of rat brains to search specifically for GnRH isoforms that have been previously 
reported – chicken II GnRH, lamprey III GnRH, and salmon GnRH. No evidence 
supporting the expression of any of these isoforms was found. These results support the 
hypothesis that mGnRH and its post-translationally modified form, Hyp9GnRH, are the 
primary, if not only, forms of GnRH expressed in rat brains. 
Previous applications of mass spectrometry to GnRH identification have been 
primarily limited to confirmation of a molecular weight (MW), and comparison to the 
corresponding MW for the amino acid sequence obtained from chemical sequence 
analysis of a putative GnRH peptide isolated after HPLC fractionation. A number of 
studies have utilized matrix-assisted laser desorption/ionization – time of flight (MALDI-
TOF) mass spectrometry to confirm MW, but did not report the amount of sample 
required (3, 5, 16, 19, 20). Other studies indicate that MW determinations by a variety of 
mass spectrometry techniques, including MALDI-TOF MS, fast atom bombardment 
(FAB) MS, and liquid secondary ion (LSI) MS, required ng – ug quantities of purified 
GnRH (21-24). Several studies have explored partial sequence determination by mass 
spectrometry in addition to MW confirmation. After proposal of a primary sequence by 
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chemical sequence analysis, the MW as well as terminal structural features and a portion 
of the internal sequence of the octopus GnRH peptide were confirmed using nano-ESI-
TOF mass spectrometry; however, the amount of sample required was not reported (4). 
Similarly, the MW and partial sequence for Lamprey I was determined by FAB-MS using 
approximately 0.8-3 ng peptide for each MS experiment (25). While the absolute 
amounts of peptide reported for chemical sequencing methods was not reported for the 
above studies, techniques such as Edman degradation typically require ng quantities of 
purified peptide. All of these methods required pre-purification of the GnRH isoforms 
prior to chemical sequencing and mass spectrometric analysis, with initial isolation of the 
putative peptides from immunoreactive HPLC fractions. The LC-MS/MS method 
reported here required approximately 10 pg for detection of a known isoform and 300-
500 pg for unknown isoforms via data-dependent experiments. Thus, not only is this LC-
MS/MS method more efficient but it also allows for identification of GnRH isoforms 
from less extracted material than previously reported methods. 
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4CHAPTER 4: A NEW METHOD FOR QUANTITATIVE MEASUREMENT OF 
MAMMALIAN GnRH ISOFORMS IN RAT BRAIN TISSUE 
 
4.1 Introduction 
Mammalian GnRH (mGnRH) was the first LH- and FSH-releasing peptide to be 
isolated and characterized (1, 2). The mammalian isoform was thought to be unique until 
other homologous isoforms were discovered, and mGnRH has subsequently been found 
in a wide variety of mammalian organisms (human, monkey, rodent) as well as bony fish 
and amphibians (3). The mGnRH peptide is released from the hypothalamus and is 
transported to the pituitary, where gonadotropin receptors facilitate release of FSH and 
LH (4). Evidence for the presence of mGnRH has also been found in extra-hypothalamic 
tissues, including mammary gland, prostate, pancreatic, and placental tissue (5). 
A modified form of mGnRH has been isolated and identified in human, sheep, 
rodent, frog and toad hypothalamus; this modified form is distinguished from mGnRH by 
a hydroxylated-proline in position 9 and is commonly referred to as hydroxyproline9 
GnRH or Hyp9GnRH (6-8). The modification to the proline residue is post-translational, 
achieved through the action of prolyl-hydroxylase enzymes; alteration at the proline 
residue confers greater resistance to enzymatic degradation compared to mGnRH (6). 
Relative distribution of Hyp9GnRH as compared to mGnRH in brain tissue is higher in 
tissues from fetal and young rats than in those from adults (6, 7), and in vitro experiments 
have demonstrated that release of Hyp9GnRH may differ from that of mGnRH during 
physiological development (9).  Additionally, Hyp9GnRH has been demonstrated to 
induce release of LH and FSH in-vitro and in-vivo, and is thought to have a role in 
regulation of these gonadotropins (10). 
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Accurate measurements of concentrations in tissue or other biological matrices 
are essential for further study of differential occurrence of Hyp9GnRH and mGnRH not 
only in rats but in other mammalian species as well. Current methods rely on lengthy 
chromatographic procedures to assure adequate separation of potential GnRH isoforms 
prior to radioimmunoassay (RIA) analysis; these methods typically measure Hyp9GnRH 
and mGnRH collected in fractions from the chromatographic assay, utilizing multiple 
antibodies with differing cross-reactivities to enhance selectivity (6, 7, 9). Sample 
throughput would be greatly enhanced if the multiple chromatographic separation steps 
and detection steps could be combined into one method, using a technique such as LC-
MS/MS. An LC-MS/MS method would also enable simultaneous measurement of 
Hyp9GnRH and mGnRH concentrations in one sample, since these isoforms would be 
chromatographically separated and detected based on their distinct molecular weights. 
Development of an optimal LC-MS/MS method for accurate and precise 
quantitation of peptides relies on the use of a calibration curve and an appropriate internal 
standard. The internal standard should be a stable-isotope labeled analogue of the analyte 
or an analogue having a very similar chemical structure, and hence, similar chemical 
behavior to the analyte over the course of the experiment (11, 12). An additional 
challenge for assays of endogenous peptides is the identification of an appropriate 
substitute matrix for standard preparation; this was especially problematic for this project, 
in that all rat brains (irrespective of age or gender) were expected to have measurable 
levels of Hyp9GnRH and mGnRH. 
Assessment of accuracy and precision of an LC-MS/MS method as well as 
evaluation of critical parameters such as linearity of the calibration curve, selectivity of 
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the method, analyte and internal standard recovery, in-process stability, and storage 
stability are best accomplished through validation of the proposed method (13, 14). While 
validation of bioanalytical methods is carried out most rigorously in the fields of clinical 
chemistry and pharmaceutical analysis, where specific regulatory criteria must be met, 
the elements of validation described above are applicable to cases such as this research 
where no specific criteria were defined a priori. 
 We were able to develop and validate an LC-MS/MS method capable of accurate 
and precise measurement of Hyp9GnRH and mGnRH in brain tissues collected from 
Sprague-Dawley rats. This is the first report of simultaneous quantitative measurements 
of Hyp9GnRH and mGnRH in any biological matrix, and to our knowledge, the first 
report of a rigorously validated method supporting the measurement of endogenous 
GnRH in tissue samples. 
Previously reported quantitative methods for Hyp9GnRH and mGnRH in tissue 
samples require two to three chromatographic steps, with fractions collected from each 
chromatographic separation evaluated for immunoreactive-GnRH by RIA prior to 
application in the next chromatographic experiment (6, 7, 9). Our method eliminates the 
need for antibody-related detection of GnRH isoforms by utilizing mass spectrometric 
detection; not only does this allow for simultaneous detection of Hyp9GnRH and mGnRH 
during a single chromatographic experiment based on their differing masses, but also it 
improves selectivity of the method regarding potential peptide fragments or  post-
translationally modified isoforms. Additionally, the method is self-correcting for 
recovery due to the use of an internal standard and calibration standards prepared in 
tissue samples, unlike RIA-based methods which require correction by a pre-determined 
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factor assumed to be constant from experiment to experiment. Experimental and long-
term stability were demonstrated during validation, parameters which have not been 
previously reported for Hyp9GnRH and mGnRH in tissue samples. Finally, the LC-
MS/MS method greatly improves upon efficiency for Hyp9GnRH and mGnRH 
quantitation by eliminating lengthy multi-day RIA incubation steps. 
Potential applications of the new methodology include continued research 
regarding differential expression of Hyp9GnRH relative to mGnRH as the distinct 
functions of these peptides are further investigated. In addition, the assay may have 
clinical relevance for monitoring the up- or down-regulation of Hyp9GnRH and mGnRH 
release after dosing with GnRH agonist- or antagonist-compounds in animal models. 
Finally, this methodology can be adapted to measurement of other GnRH isoforms, 
requiring only that synthetic reference standard material be available and appropriate 
blank matrices can be identified. 
4.2 EXPERIMENTAL 
Chemicals and Reagents 
Glacial acetic acid and trifluoroacetic acid (TFA) were purchased from J.T. Baker 
(Phillipsburg, NJ, USA). Acetonitrile and methanol were purchased from Burdick & 
Jackson (Muskegon, MI, USA). Water was either purchased from Burdick & Jackson 
(Muskegon, MI, USA) or supplied by an in-house Vantage reverse-osmosis system (US 
Filter, Colorado Springs, CO, USA). Bond Elut C18 solid-phase extraction cartridges 
(200 mg) were purchased from Varian (Palo Alto, CA, USA). 
Ultramark 1621 and l-methionyl-arginyl-phenylalanyl-alanine (MRFA) were 
purchased from ThermoFinnigan (San Jose, CA, USA). Caffeine was purchased in 
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powder form from Sigma-Aldrich (St. Louis, MO, USA). mGnRH (native and free acid 
forms) and chicken II GnRH standards (cGnRH-II) were purchased from BAChem 
(Torrance, CA, USA). Hyp9GnRH was purchased from California Peptide Research 
(Napa, CA, USA). 
Sprague-Dawley rat brains and guinea pig brains were obtained frozen over dry 
ice from BioChemed Services (Winchester, VA, USA) and were stored at -70°C prior to 
analysis. LHRH ELISA kits were purchased from BAChem, Peninsula Labs division 
(San Carlos, CA). 
Standard preparation 
Stock standards of each GnRH peptide were prepared at 100 µg mL-1 in 
deoxygenated H2O. Subsequent dilutions were made into 50/50 acetonitrile/ H2O to 
minimize adsorption to tube and vial walls. Calibration standard spiking solutions were 
prepared at 4, 10, 20, 40, 100, 200 and 400 pg µL-1 such that 50 µL added to brain 
homogenate produced calibration standards ranging from 200 – 20000 pg total per tissue 
extracted. Two internal standard candidates were evaluated, mGnRH-free acid (mGnRH-
fa) and chicken II GnRH (cGnRH-II); a stock solution containing 100 pg µL-1 mGnRH-fa 
and cGnRH-II was prepared such that 20 µL added to brain homogenates produced 2000 
pg total per tissue extracted. Quality control samples were prepared by adding 30 µL of 
the 20 pg µL-1 calibration spiking solution into homogenate to produce the LOW QC at 
600 pg, by adding 20 µL of the 100 pg µL-1 calibration spiking solution into homogenate 
to produce the MID QC at 2000 pg and by adding 37.5 µL of the 400 pg µL-1 calibration 
spiking solution into homogenate to produce the HIGH QC at 15000 pg. 
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Extraction procedure 
Rat and guinea pig brains were homogenized in polypropylene test tubes with 3 
mL acetonitrile using a Tissue-Tearor tissue homogenizer (Biospec Products, 
Bartlesville, OK, USA), with an additional 2 mL acetonitrile used to rinse the 
homogenizer probe and combined with the homogenate. After addition of calibration and 
internal standard spiking solutions to the samples, homogenates were vortexed and then 
centrifuged at 2500 g, 4ºC for 30 minutes. The supernatant was evaporated under 
nitrogen at 65ºC and reconstituted in 3 mL of the loading solution, which consisted of 
water:acetic acid:TFA (96:3:1, volume/volume). 
Solid phase extraction (SPE) was used to isolate GnRH from the brain 
homogenate samples. The SPE cartridges were preconditioned with 3 mL methanol 
followed by 3 mL of the loading solution. The reconstituted supernatant was transferred 
to the cartridges, which were subsequently washed with 3 mL loading solution followed 
by 3 mL loading solution:methanol (70:30, volume/volume). Samples were eluted with 3 
mL 3% acetic acid:methanol (30:70, volume/volume), which was collected and 
evaporated under nitrogen at 70ºC. Samples were reconstituted in 100 µL 3% acetic 
acid:methanol (95:5, volume/volume), vortexed for 30 seconds and transferred to glass 
autosampler vials for analysis. 
HPLC-MS/MS 
HPLC separations were performed using a Hewlett-Packard 1100 series binary 
pump and autosampler with vacuum degasser (Palo Alto, CA, USA) connected to a 
Phenomenex Luna C8(2) 50 x 1.0 mm column, 5µ particle size (Torrance, CA, USA). 
Mobile phase A consisted of 0.5% (volume/volume) acetic acid in water and mobile 
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phase B consisted of 0.5% (vol/vol) acetic acid in acetonitrile. A gradient program 
increasing from 5% B to 20% B over 15 minutes was used to achieve separation of the 
GnRH peptides. The volume of sample extract injected was 50 µL, and column effluent, 
at 100 µL min-1, was directed into the electrospray source of the mass spectrometer 
without splitting. 
All experiments were performed using a Finnigan LCQ Deca quadrupole ion trap 
mass spectrometer (San Jose, CA, USA) operated in positive electrospray mode. The 
electrospray source was fitted with a stainless steel needle. Calibration of the mass 
spectrometer was performed using a mixture of caffeine, MRFA, and Ultramark 1621 as 
recommended by the manufacturer (15).  
Optimization of source conditions was performed while infusing sample from a 
syringe pump into mobile phase flow at 100 µL min-1. The following source settings were 
selected as optimal: sheath flow (Nitrogen) - 100 units, auxiliary flow - off, source 
voltage – 5.0 kV, capillary temperature – 275°C, and capillary voltage – 7.0 V. 
Automatic gain control (AGC) was set to on, with a full AGC target of 5000000.  
The MS-MS acquisition was divided into three segments, with data acquired over 
the course of the chromatographic run. The scan events in each segment, as well as mass 
spectrometry settings for the scan events, are shown in Table 4.1. The default isolation 
width was set to 3.0 and the activation Q was set to 0.250 with an activation time of 30 
msec for all peptides. 
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Table 4.1. Scan events and settings for MS-MS quantitation 
 
GnRH Peptide Precursor Ion (m/z) 
Event Time 
(min) 
Collision 
Energy (%)
Fragment Mass 
Range Scanned 
(m/z) 
Hyp9GnRH 1198.5 8.00-10.50 35 325-1200 
mGnRH 1182.5 10.50-12.25 35 325-1200 
mGnRH-fa 1183.5 12.25-15.00 35 325-1200 
cGnRH-II 1236.5 12.25-15.00 30 340-1250 
 
 
 
Validation Experiments 
Validation of method performance was conducted to verify that the extraction and 
instrumental methods provided accurate and reproducible results over multiple instances 
of use. Key parameters of interest for the intended application in this study were accuracy 
and precision, extraction recovery, stability during sample processing, and long-term 
storage stability. 
Calibration standards and quality control (QC) samples were prepared with each 
validation run. Because the GnRH peptides of interest are endogenous in rat brain tissue, 
guinea pig brains were evaluated and found to be a suitable blank matrix. To provide a 
tissue matrix of comparable mass to the rat brain samples, guinea pig brains were halved 
laterally and then spiked with the appropriate calibration and internal standard solutions 
for calibration and QC sample preparation. 
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Each validation batch included seven calibration standards containing Hyp9GnRH 
and mGnRH ranging from 20 to 20000 pg/tissue; calibration standards were prepared in 
singlicate and were distributed throughout the analytical run sequence on the instrument. 
QC samples were prepared in duplicate at three levels for each run, excepting one 
validation run in which five replicates at each level were prepared and analyzed to assess 
accuracy and precision. A blank matrix sample, prepared from guinea pig brain, was also 
included with each validation batch to monitor possible cross-contamination and 
instrument carryover. Reconstructed ion chromatograms were prepared for Hyp9GnRH, 
mGnRH, mGnRH-fa and cGnRH-II from which peak areas were integrated; ratios of 
peak area analyte to peak area internal standard were used to prepare calibration curves. 
After determining a suitable calibration model, least-squares linear-regression analysis 
with 1/x2 weighting was applied to each validation run, from which back-calculated 
concentrations for the calibration standards, QCs and samples were derived. All 
regressions were performed using XCalibur version 1.2 (Thermo, San Jose, CA, USA). 
Extraction recovery was assessed by comparison of samples prepared from rat 
brains spiked with 20 ng Hyp9GnRH and mGnRH and 2 ng mGnRH-fa to samples 
prepared from rat brain extracts spiked with the same amounts post-extraction and 
cleanup. The recovery experiments were designed to compare pre- and post-extraction 
spiked samples such that any influence of sample matrix components on ionization within 
the electrospray source of the mass spectrometer would be normalized (16, 17). 
To assess in-process stability, rat brains subjected to room temperature for 2 hours 
prior to processing and rat brains subjected to 3 freeze-thaw cycles prior to processing 
were compared to rat brains thawed and processed immediately. Stability of Hyp9GnRH 
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and mGnRH after long-term freezer storage was explored by comparing brains stored for 
21 days prior to extraction with brains stored for 112 days prior to extraction. Stability of 
extracted samples stored at room temperature was assessed by reinjecting a set of 
calibration standards and quality control samples 27 hours after the initial analysis start 
time. Injection volume was changed to 40 µL for the second injection, as insufficient 
volume remained to allow for a 50 µL injection. 
Comparison to ELISA 
A comparison of mGnRH values determined via the new LC-MS/MS method to 
values determined using a commercially available mGnRH immunoassay was performed. 
To create equivalent samples for analysis, five male and five female rat brains were 
homogenized with the resulting supernatant divided equally. The aliquot reserved for LC-
MS/MS analysis was spiked with internal standard solution (mGnRH-fa). No internal 
standard was added to the aliquot reserved for the immunoassay to eliminate any 
response due to potential cross-reactivity with mGnRH-fa. All samples were extracted by 
the solid phase extraction method described above, with final reconstitution in assay 
buffer for the ELISA procedure or in 95:5 3% acetic acid:methanol for the LC-MS/MS 
method. Attempts to assess control samples prepared from guinea pig brains by the 
ELISA method were hampered by suspected cross-reactivity of guinea pig GnRH with 
the anti-mGnRH antibody. 
The 96-well plates provided with the ELISA kit were utilized per kit instructions 
for competitive enzyme immunoassay and subsequently transferred to a Spectramax250 
plate reader (Molecular Devices, Sunnyvale, CA, USA) for determination of absorbance 
at 450 nm. Data from the Spectramax was transferred to SigmaPlot 10.0, where sigmoidal 
107 
 
 
(3-parameter) regression analysis was performed with results corrected for recovery 
losses during extraction. Data provided by the manufacturer specified that the antibody 
had crossreactivity of 0.1% or less with lamprey III GnRH, salmon GnRH, and several 
synthetic analogues of mGnRH; no data was provided for cross-reactivity with 
Hyp9GnRH, mGnRH-fa or gpGnRH (18). 
Quantitative Analysis of Hyp9GnRH and mGNRH in Rat Brain 
Concentrations of Hyp9GnRH and mGnRH in 16 male and 15 female rat brains 
(Sprague-Dawley) were determined using the validated method and are reported below 
along with a comparison to previous reports in the literature. To our knowledge, this is 
the first method reported to provide simultaneous quantification of multiple GnRH 
isoforms. 
4.3 RESULTS AND DISCUSSION 
Selection of blank matrix 
 Selection of an appropriate matrix for preparation of calibration standards and 
quality control samples for exogenous compounds is straightforward in that blank tissue 
or fluid can be obtained, which is then spiked with known amounts of the analyte. Thus, 
for accurate quantification of endogenous GnRH isoforms, a different strategy was 
required. Following unsuccessful attempts to reduce GnRH concentrations to 
undetectable levels via degradation at extended room temperature storage or gross 
removal of hypothalamic tissues, it became clear that a matrix other than rat brain tissue 
would be needed for preparation of calibration standards and quality control samples. 
 While standards of known concentration can be prepared and extracted from neat 
solutions, there is no compensation for the influence of matrix on recovery or instrument 
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signal. Standard addition methods can achieve accurate quantitative results with 
endogenous compounds. However, because standards are prepared from aliquots of the 
actual sample, standard addition requires a generous amount of material for each sample 
tested. Recently, “surrogate analytes” have been proposed as a strategy for accurate 
quantitation of endogenous compounds (19); this technique utilizes a surrogate (usually 
an isotopically-labeled compound) that closely mimics the behavior of the endogenous 
analyte for calibration standards. 
 Given that the sample material for this project was limited to single brain tissues 
and that isotopically-labeled forms of Hyp9GnRH and mGnRH were not readily 
available, we chose to investigate whether guinea pig might provide a suitable brain 
tissue matrix for preparation of Hyp9GnRH and mGnRH standards. There is some 
discrepancy in the literature regarding whether mGnRH is expressed in guinea pig; while 
the initial work proposing the structure of gpGnRH failed to isolate mRNA specific to 
mGnRH, a later study suggested coexpression of gpGnRH with mGnRH (20, 21). In this 
context, it seemed prudent to establish the presence or absence of a detectable amount of 
mGnRH in guinea pig brain before proceeding with use of this tissue for preparation of 
calibration standards and quality control samples. 
 To determine whether mGnRH was detectable, a single intact guinea pig brain 
was extracted and subjected to a targeted product ion analysis experiment by LC-MS/MS 
as described for single rat brains in Chapter 3. Neither Hyp9GnRH nor mGnRH was 
detected. However, a strong signal for gpGnRH was observed with a fragmentation 
pattern suggestive of the sequence predicted for gpGnRH based on mRNA (20), 
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indicating that extraction of GnRH from the brain was successful and mGnRH, if present, 
was undetectable. 
Assay range and calibration model 
During initial method development, a reasonable lower limit of quantitation 
(LLOQ) for extracted samples was determined to be 200 pg Hyp9GnRH and mGnRH. 
The upper limit of quantitation (ULOQ) for the calibration curve was set at 20000 pg 
Hyp9GnRH and mGnRH. Chromatograms for unspiked (blank) guinea pig brain and for 
guinea pig brains spiked with 200 and 20000 pg Hyp9GnRH and mGnRH are shown in  
Figure 4.1. The signal to noise (S/N) ratios at the LLOQ concentration were 15 and 21, 
respectively, for Hyp9GnRH and mGnRH. The effect of fragment ion selection for 
quantitation on S/N ratios is discussed further in below sections.
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Figure 4.1. Reconstructed ion chromatograms of m/z 1198.5 (precursor ion for 
Hyp9GnRH) and m/z 1182.5 (precursor ion for mGnRH) for extracted calibration 
standards at 200, 500, 1000, 2000, 5000, 10000, and 20000 pg/tissue and an extracted 
blank sample. 
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Two internal standards were chosen for evaluation during method validation, 
mGnRH in free acid form (mGNRH-fa) and chicken II GnRH (cGnRH-II). mGnRH-fa 
was chosen for structural similarity and similar fragmentation behavior as the analytes. 
cGnRH-II was selected because it eluted most closely to mGnRH under the HPLC 
conditions employed as compared to other GnRH isoforms available in our laboratory 
(including chicken I GnRH, lamprey III GnRH, salmon GnRH, and seabream GnRH). 
The structures of mGnRH, mGNRH-fa, Hyp9GnRH and cGnRH-II are shown in Figure 
4.2 and ESI-MS/MS spectra for each isoform are shown in Figure 4.3. mGnRH-fa was 
ultimately selected as the more appropriate internal standard for both Hyp9GnRH and 
mGnRH, as accuracies were improved over those obtained with cGnRH-II as the internal 
standard. This result may be because the MS/MS fragmentation pattern of mGnRH-fa 
was more similar to that of Hyp9GnRH and mGnRH than that of cGnRH-II, making 
mGNRH-fa a better analogue internal standard. 
A characteristic of quadrupole ion trap mass spectrometers is that product ion 
scans over a wide mass range can be detected in a shorter scan time than would be 
possible with triple quadrupole mass spectrometers. While triple quadrupole mass 
spectrometers are commonly used and perform well for quantitative applications, analysis 
is typically by selected reaction monitoring (SRM) whereby a single fragment mass is 
monitored. The capability of the ion trap to provide MS/MS scan data in a time frame 
compatible with chromatographic elution is a distinct advantage for analyses involving 
compounds such as peptides which undergo fragmentation into many ions because the 
signal from multiple fragment ions can be summed to produce a more abundant signal 
than could be achieved from a single fragment ion (12, 22). 
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Figure 4.2.  Chemical structures of a) mGnRH, b) mGnRH-fa, c) Hyp9GnRH and d) 
cGnRH-II. 
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Figure 4.3.  Product ion spectra of a) Hyp9GnRH, m/z 1198.5, b) mGnRH, m/z 
1182.5, c) mGnRH-fa, m/z 1183.5, and d) cGnRH-II, m/z 1236.5.  
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To determine an optimal quantification strategy given the multiple fragment ions 
produced, results from the first validation run were evaluated after quantification based 
on the single most abundant fragment ion, the sum of the two most abundant fragment 
ions, and so forth up to a total of five fragment ions for each analyte and internal standard 
compound. The transitions evaluated are shown in Table 4.2. Due to the homologous 
amino acid sequences of the GnRH peptides, four of the five ions evaluated in this 
exercise were common fragments to Hyp9GnRH, mGnRH and mGNRH-fa. The fifth ion 
was the consequence of dehydration of the precursor ion, and the m/z associated with this 
fragment ion varied accordingly. 
 
 
Table 4.2. Mass transitions selected for quantitative comparison 
GnRH Peptide 
(precursor m/z) 
Fragment Ions Listed in 
Order of Descending 
Abundance 
(fragment ion type) 
Hyp9GnRH 
(1198.5) 
mGnRH 
(1182.5) 
mGnRH-fa 
(1183.5) 
1 
(b6+) 
742.2 742.2 742.2 
2 
(b8+) 
1011.4 1011.4 1011.4 
3 
(b5+-H2O) 
667.2 667.2 667.2 
4 
(b4+-H2O) 
504.1 504.1 504.1 
5 
(MH+-H2O) 
1180.6 1164.6 1165.5 
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To evaluate results obtained from the quantitative comparison, relative error 
(residuals) for each calibration standard and QC in the first validation experiment as well 
as the mean of the absolute relative error for each iteration of the run are shown in Table 
4.3 for Hyp9GnRH and Table 4.4 for mGnRH. A linear regression with 1/x2-weighting 
was used for this comparison. Results can be seen to improve as additional ions are added 
until five ions are included in the summed signal, when a slight increase in the mean 
residual is observed. 
 
 
Table 4.3. Relative Errors for Hyp9GnRH, Validation Run #1 
 
% Relative Error 
 
(# Ions included in quantitative analysis) 
Stds & QCs (1) (2) (3) (4) 
 
(5) 
C1 (200 pg) -4.0 -0.1 0.7 0.1 0.6 
C2 (500 pg) 8.3 -1.9 -3.4 -2.8 -2.5 
C3 (1000 pg) 9.3 6.8 5.4 6.4 3.1 
C4 (2000 pg) -14.7 -7.9 -8.2 -5.6 -6.5 
C5 (5000 pg) 8.2 7.9 12.2 7.9 11.6 
C6 (10000 pg) 6.4 1.9 2.3 -0.1 0.8 
C7 (20000 pg) -13.5 -6.7 -8.9 -6.0 -7.2 
LOW QC (600 pg) -3.4 -0.1 2.8 5.5 7.5 
LOW QC (600 pg) -14.1 2.2 6.3 5.8 6.6 
MID QC (2000 pg) 21.9 24.7 21.3 12.1 13.0 
MID QC (2000 pg) 6.5 5.7 -0.8 1.2 -0.3 
HIGH QC (15000 pg) -4.1 2.2 0.8 -3.8 -4.1 
HIGH QC (15000 pg) -6.2 -2.4 1.3 -1.4 1.2 
Mean |relative error| 9.3 5.4 5.7 4.5 5.0 
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Table 4.4. Relative Errors for mGnRH, Validation Run #1 
 
 
% Relative Error 
 
(# Ions included in quantitative analysis) 
Stds & QCs (1) (2) (3) (4) 
 
(5) 
C1 (200 pg) 0.6 0.9 -0.6 0.3 0.8 
C2 (500 pg) -10.2 -12.0 -7.7 -10.8 -11.2 
C3 (1000 pg) 23.8 23.6 22.9 23.2 22.4 
C4 (2000 pg) -13.7 -8.0 -10.1 -7.3 -10.4 
C5 (5000 pg) 1.3 -0.3 5.2 3.9 7.8 
C6 (10000 pg) 4.8 0.1 -0.3 -2.4 -2.8 
C7 (20000 pg) -6.6 -4.3 -9.5 -7.1 -6.7 
LOW QC (600 pg) -8.9 -1.1 -1.4 1.9 5.9 
LOW QC (600 pg) -25.2 -10.2 -9.4 -8.6 -11.8 
MID QC (2000 pg) 19.3 21.3 19.2 9.4 8.6 
MID QC (2000 pg) 13.2 8.1 -1.6 1.3 -1.6 
HIGH QC (15000 pg) -10.0 -2.0 -2.7 -3.9 -1.0 
HIGH QC (15000 pg) -6.2 -6.7 -4.2 -7.5 -5.0 
Mean |relative error| 11.1 7.6 7.3 6.7 7.4 
 
 
 
Reconstructed ion chromatograms of the 200 pg calibration standard for each 
iteration of this exercise are shown in Figure 4.4 for Hyp9GnRH and Figure 4.5 for 
mGnRH. While signal intensity increases with the addition of each successive ion, a 
potential interference peak immediately prior to mGnRH is observed when five ions are 
included in the reconstructed ion chromatogram. Additionally, the signal to noise ratio is 
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decreased to less than 10 upon addition of the MH+-H2O fragment ion in the 
reconstructed ion chromatogram. Given that the smallest mean relative error was 
obtained from the summed signal of four ions, that a potential interference to mGnRH 
was observed upon the inclusion of a fifth ion, and that signal to noise ratios were 
lessened by addition of the fifth ion, quantification for both Hyp9GnRH and mGnRH was 
based on the four most abundant ions in Table 4.2 and the MH+-H2O ion fragment was 
dropped from the quantitative analysis program. 
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Figure 4.4. Reconstructed ion chromatograms of m/z 1198.5 (precursor ion for 
Hyp9GnRH) for an extracted 200 pg calibration standard, shown in increasing 
order of ions included in reconstruction. S/N and integrated areas are shown above 
each peak. 
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Figure 4.5. Reconstructed ion chromatograms of m/z 1182.5 (precursor ion for 
mGnRH) for an extracted 200 pg calibration standard, shown in increasing order of 
ions included in reconstruction. S/N and integrated areas are shown above each 
peak. 
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Selection of a suitable regression model was performed by evaluating data from 
four analytical batches, each containing calibration standards prepared at seven 
concentration levels between 200-20000 pg/tissue and QC samples prepared at three 
concentration levels within the calibration range. Relative errors were compared for the 
following regression models: linear with no weighting, linear with 1/x weighting and 
linear with 1/x2 weighting. Plots of relative errors by concentration (calibration standards 
and QC samples) are shown for Hyp9GnRH in Figure 4.4 and mGnRH in Figure 4.6, and 
the mean absolute relative error for each validation run is shown in Table 4.7 for 
Hyp9GnRH and mGnRH. Coefficients of determination (R2) for both analytes calculated 
using the different weighting schemes are shown in Table 4.6. The application of 
weighting greatly improved the fit at lower concentrations and reduced the mean relative 
error. For both Hyp9GnRH and mGnRH, R2 decreased in most instances as 1/x and 1/x2 
weighting were applied; however, R2 was greater than 0.98 for all runs. Therefore, a 
linear calibration model with 1/x2 weighting was chosen. 
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Figure 4.6.  Relative error plots from regression models evaluated for Hyp9GnRH 
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Figure 4.7.  Relative error plots from regression models evaluated for mGnRH 
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Table 4.5. Mean |% Relative Error| 
 
 Mean |%RE| Hyp9GnRH 
Mean |%RE| 
mGnRH 
Run# none 1/x 1/x2 none 1/x 1/x2 
1 16.4 5.34 4.53 18.2 7.75 6.73 
2 22.7 8.16 7.28 23.7 8.01 7.51 
3 9.27 4.67 4.54 51.3 8.96 6.23 
4 7.39 6.79 6.34 9.86 5.23 5.19 
Mean 13.9 6.24 5.67 25.8 7.49 6.42 
 
 
 
Table 4.6. Coefficients of Determination (R2) 
 
 Hyp9GnRH mGnRH 
Run# none 1/x 1/x2 none 1/x 1/x2 
1 0.9981 0.9971 0.9960 0.9987 0.9960 0.9826 
2 0.9960 0.9960 0.9938 0.9979 0.9966 0.9918 
3 0.9992 0.9992 0.9991 0.9802 0.9820 0.9891 
4 0.9955 0.9940 0.9909 0.9993 0.9985 0.9969 
Mean 0.9972 0.9966 0.9950 0.9940 0.9933 0.9901 
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Linearity of calibration curve 
 The calibration curve was constructed to measure 200-20000 pg/tissue 
Hyp9GnRH and mGnRH. None of the seven calibration standards were excluded from 
any of the regression analyses, which were performed using a 1/x2-weighted linear 
regression. In validation run 4, a loss of instrument sensitivity prevented detection of 
Hyp9GnRH and mGnRH in the 200 pg/tissue calibration standard; this problem was 
rectified by cleaning of the instrument and has not recurred. Slope, intercept and R2 
values for each regression analysis during validation are presented in Table 4.7. 
Calibration curves constructed from the largest batch, validation run 4, for Hyp9GnRH 
and mGnRH are presented in Figures 4.8 and 4.9, respectively. 
  
 
Table 4.7. Calibration Curve Parameters 
 
 Hyp9GnRH mGnRH 
Run# Slope Intercept R2 Slope Intercept R2 
1 0.000328 0.000305 0.9960 0.000605 0.00894 0.9826 
2 0.000365 0.00613 0.9938 0.000671 0.00437 0.9918 
3 0.000325 0.00388 0.9991 0.000576 0.0134 0.9891 
4 0.000353 -0.00167 0.9909 0.000669 0.00211 0.9969 
Mean 
(%RSD) 
0.000343 
(5.67) 
0.00216 
(162) 
0.9950 
(0.348) 
0.000630 
(7.52) 
0.00721 
(69.6) 
0.9901 
(0.601) 
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Figure 4.8.  Calibration curve for Hyp9GnRH, validation run 4 
 
 
 
 
Figure 4.9.  Calibration curve for mGnRH, validation run 4 
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Back-calculated concentrations for Hyp9GnRH and mGnRH in calibration 
standards are presented in Tables 4.8 and 4.9, respectively. Inter-run accuracy ranged 
from 95.5 to 106% for Hyp9GnRH and 92.1 to 108% for mGnRH. Inter-run precision, 
reported as relative standard deviation (%RSD), ranged from 2.34 to 9.40% for 
Hyp9GnRH and 3.57 to 10.2% for mGnRH. These data further suggest that linear-
regression with 1/x2-weighting provided a suitable model for fitting the data obtained 
from these experiments. 
 
 
Table 4.8. Back-calculated values for Hyp9GnRH calibration standards 
 Nominal Concentration (pg/tissue) 
Run# 200 500 1000 2000 5000 10000 20000 
1 200 486 1060 1890 5400 9990 18800 
2 192 527 1110 1970 4800 10300 18100 
3 200 499 1010 1920 5140 10300 19500 
4 * 492 1050 2020 4330 11000 20000 
        
Mean 197 501 1060 1950 4920 10400 19100 
%Accuracy 98.7 100 106 97.5 98.4 104 95.5 
%RSD 2.34 3.62 3.89 2.93 9.40 4.11 4.34 
*not detected  
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Table 4.9. Back-calculated values for mGnRH calibration standards 
 Nominal Concentration (pg/tissue) 
Run# 200 500 1000 2000 5000 10000 20000 
1 201 446 1230 1850 5200 9760 18600 
2 188 555 1080 2050 4930 9710 17800 
3 199 509 966 1970 5630 10700 16800 
4 * 490 1050 2010 4610 10200 20500 
        
Mean 196 500 1080 1970 5090 10100 18400 
%Accuracy 98.0 100 108 98.5 102 101 92.1 
%RSD 3.57 9.03 10.2 4.39 8.48 4.57 8.51 
*not detected  
 
 
Accuracy and precision 
Accuracy and precision of the method were assessed by including quality control 
samples at 600 pg/tissue (LOW QC), 2000 pg/tissue (MID QC) and 15000 pg/tissue 
(HIGH QC) in each run. Validation runs 1-3 included duplicate QC samples at each level 
for assessment of inter-run accuracy and precision, while validation run 4 included five 
replicates at each level for assessment of intra-run accuracy and precision. QC results for 
Hyp9GnRH and mGnRH are presented in Tables 4.10 and 4.11, respectively. Intra-run 
accuracy ranged from 94.0 – 110% for Hyp9GnRH and 98.4 – 111% for mGnRH, with 
intra-run precision ranging from 3.24 – 8.84% for Hyp9GnRH and 4.43 – 8.16% for 
mGnRH. Inter-run accuracy ranged from 100 - 102% for Hyp9GnRH and 95.6 – 98.7% 
for mGnRH, with inter-run precision (%RSD) ranging from 8.68 – 10.8% for Hyp9GnRH 
and 6.85 – 9.65% for mGnRH. 
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Table 4.10. Back-calculated values for Hyp9GnRH quality control samples 
LOW QC (600 pg/tissue) 
Run 1  Run 2  Run 3  Run 4 
633  525  597  640 
635  604  685  711 
      568 
      703 
      677 
     
 Inter-day (n=6)   Intra-day (n=5) 
 Mean 613   Mean 660 
 %ACC 102   %ACC 110 
 %RSD 8.68   %RSD 8.84 
       
MID QC (2000 pg/tissue) 
Run 1  Run 2  Run 3  Run 4 
2240  1810  1990  1880 
2020  1730  2260  1810 
      1810 
      1990 
      1910 
     
 Inter-day (n=6)   Intra-day (n=5) 
 Mean 2010   Mean 1880 
 %ACC 100   %ACC 94.0 
 %RSD 10.8   %RSD 4.02 
       
HIGH QC (15000 pg/tissue) 
Run 1  Run 2  Run 3  Run 4 
14400  12700  16300  14900 
14800  15900  16400  14300 
      13600 
      14300 
      14200 
     
 Inter-day (n=6)   Intra-day (n=5) 
 Mean 15100   Mean 14300 
 %ACC 101   %ACC 95.1 
 %RSD 9.43   %RSD 3.24 
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Table 4.11. Back-calculated values for mGnRH quality control samples 
LOW QC (600 pg/tissue) 
Run 1  Run 2  Run 3  Run 4 
611  541  575  636 
549  611  665  704 
      614 
      679 
      696 
     
 Inter-day (n=6)   Intra-day (n=5) 
 Mean 592   Mean 666 
 %ACC 98.7   %ACC 111 
 %RSD 7.85   %RSD 5.87 
       
MID QC (2000 pg/tissue) 
Run 1  Run 2  Run 3  Run 4 
2190  1830  1850  2110 
2030  1710  2130  1850 
      2160 
      1940 
      1790 
     
 Inter-day (n=6)   Intra-day (n=5) 
 Mean 1960   Mean 1970 
 %ACC 97.8   %ACC 98.5 
 %RSD 9.65   %RSD 8.16 
       
HIGH QC (15000 pg/tissue) 
Run 1  Run 2  Run 3  Run 4 
14400  13100  16000  15700 
13900  13900  14700  14800 
      14900 
      13900 
      14500 
     
 Inter-day (n=6)   Intra-day (n=5) 
 Mean 14300   Mean 14800 
 %ACC 95.6   %ACC 98.4 
 %RSD 6.85   %RSD 4.43 
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Recovery 
Results obtained from samples prepared to assess recovery are shown in Table 
4.12. The five samples spiked prior to extraction were designated as “extracted”, while 
the five samples spiked post-extraction were designated “non-extracted”. Mean areas 
derived from the reconstructed ion chromatograms were compared for Hyp9GnRH, 
mGnRH and mGnRH-fa. %Recovery (%REC) was calculated as a ratio of the mean area 
from the extracted samples to the mean area from the non-extracted samples. Results 
were similar, with 44.8% Hyp9GnRH recovered, 51.7% mGnRH recovered, and 46.3% 
mGnRH-fa recovered. 
 
 
Table 4.12. Recovery of Hyp9GnRH, mGnRH and mGnRH-fa 
 
 Hyp9GnRH mGnRH mGnRH-fa 
 Area 
Extracted 
Area 
Nonextracted 
 Area 
Extracted 
Area 
Nonextracted 
 Area 
Extracted 
Area 
Nonextracted 
 84142541 171958909  147682906 281973711  12328887 22122647 
 85734167 189529217  141409126 273353435  12305379 24862010 
 75164616 192535276  129912990 267259826  10599715 28376566 
 83114284 195848822  142498625 265558625  11623932 26344277 
 84749569 170972721  134345940 257636670  12381540 26134739 
         
Mean 82581035 184168989  139169917 269156453  11847891 25568048 
%RSD 5.15 6.42  5.05 3.38  6.45 9.00 
%REC  44.8   51.7   46.3 
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Stability of Hyp9GnRH and mGnRH in rat brains at room temperature 
To assess the impact of room temperature storage on Hyp9GnRH and mGnRH in 
rat brains, five rat brains were extracted immediately after thawing and were compared to 
five rat brains extracted after two hours at room temperature. Results from these 
experiments are shown in Table 4.13. Means were compared using a t-test (95% 
confidence interval) and were not found to be significantly different. 
 
 
Table 4.13. Evaluation of room temperature storage on concentrations of 
Hyp9GnRH and mGnRH 
 
 Hyp9GnRH  mGnRH 
 pg/tissue 
0 hr RT 
pg/tissue 
2 hrs RT 
 pg/tissue 
0 hr RT 
pg/tissue 
2 hrs RT 
 243 199  900 797 
 230 407  1050 1480 
 277 410  1370 1860 
 348 312  1680 1590 
 277 260  1240 1250 
      
Mean 275 318  1250 1400 
Std. Dev. 46 92  301 400 
t-value 
(95% C.I.) 
tcrit=2.31 
 0.92   0.65 
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Stability of Hyp9GnRH and mGnRH in rat brains after freeze/thaw cycling 
To assess the impact of multiple freeze/thaw cycles on Hyp9GnRH and mGnRH 
in rat brains, five rat brains were extracted immediately after thawing and were compared 
to five rat brains extracted after enduring three freeze/thaw cycles. Results from these 
experiments are shown in Table 4.14. Means were compared using a t-test (95% 
confidence interval) and were not found to be significantly different. 
 
 
Table 4.14. Evaluation of 3 freeze/thaw cycles on concentrations of Hyp9GnRH and 
mGnRH 
 
 Hyp9GnRH  mGnRH 
 pg/tissue 
1 F/T cycle 
pg/tissue 
3 F/T cycles 
 pg/tissue 
1 F/T cycle 
pg/tissue 
3 F/T cycles 
 243 175  900 731 
 230 379  1050 1890 
 277 267  1370 1070 
 348 246  1680 1200 
 277 164  1240 634 
      
Mean 275 246  1250 1110 
Std. Dev. 46 86  301 497 
t-value 
(95% C.I.) 
tcrit=2.31 
 0.67   0.56 
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Stability of Hyp9GnRH and mGnRH under long-term storage conditions 
Assessment of the long-term stability of Hyp9GnRH and mGnRH in Sprague-
Dawley rat brains stored at -70ºC was performed by comparing concentrations obtained 
from five brains stored for a relatively short period of time (21 days) to five brains stored 
for over 3 months (112 days). Results from these experiments are shown in Table 4.15. 
Means were compared using a t-test (95% confidence interval) and were not found to be 
significantly different. While limited supplies prevented analysis of a larger sample set, 
evaluation of these samples does demonstrate that gross losses do not occur during long-
term storage of up to 3.5 months. Evaluation of long-term storage effects on endogenous 
GnRH in brain tissues has not been previously reported in the literature. 
 
Table 4.15. Evaluation of effect of long-term storage at -70°C on concentrations of 
Hyp9GnRH and mGnRH in rat brain 
 
 Hyp9GnRH  mGnRH 
 pg/tissue 
21 days 
pg/tissue 
112 days 
 pg/tissue 
21 days 
pg/tissue 
112 days 
male 198 231  865 996 
male 515 489  2480 2580 
male 328 348  1290 1840 
female 231 255  1290 1560 
female 341 163  1900 798 
      
Mean 323 297  1570 1550 
Std. Dev. 124 126  631 710 
t-value 
(95% C.I.) 
tcrit=2.31 
 0.32   0.02 
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Stability Hyp9GnRH and mGnRH in sample extracts 
The stability of Hyp9GnRH and mGnRH in sample extracts after completion of 
processing was assessed by re-injecting a set of calibration standards and quality control 
samples after 24 hours at room temperature. Results for calibration standards and quality 
control samples were compared by evaluating a linear regression of the back-calculated 
concentrations obtained from the reinjection assay against the back-calculated 
concentrations obtained from the initial assay. The resulting slope, intercept, and 
coefficient of determination (R2) are shown in Table 4.16. Slope and intercept are 
presented with 95% confidence limits. A perfect correlation would yield a slope = 1 and 
an intercept = 0. For both Hyp9GnRH and mGnRH, the ideal slope and intercept fall 
within the 95% confidence limits. Based on these results, samples stored at room 
temperature and subsequently analyzed up to 24-hours post-extraction should provide 
results comparable to those obtained from analysis immediately post-extraction. 
 
 
Table 4.16. Regression results for evaluation of re-injection stability  
 
 Hyp9GnRH  mGnRH 
    
Slope 1.01 ± 0.08  0.961 ± 0.046 
Intercept -58 ± 716  80 ± 398 
R2 0.987  0.995 
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Comparison to ELISA assay 
To create equivalent samples for measurement by both ELISA and LC-MS/MS, 
five male rat brains and five female rat brains were homogenized and extracted using the 
validated method, with the samples split into equal aliquots. After the final evaporation 
step, one portion was allocated to LC-MS/MS analysis and reconstituted with 95:5 3% 
acetic acid:methanol while the other portion was allocated to ELISA and reconstituted 
with the ELISA buffer solution. 
Recovery of the internal standard in the comparison samples differed from  
recovery in the calibration standards (as evaluated by comparison of mGnRH-fa area 
counts for samples versus calibration standards); therefore, external standard calibration 
(1/x2-weighted linear regression) was used to determine mGnRH concentrations. The 
accuracy of back-calculated concentrations for calibration standards ranged from 94.2 to 
106%, while the accuracies of quality control standards ranged from 85.1 to 106%; thus, 
use of an external standard regression for LC-MS/MS quantitation was deemed valid for 
this experiment. 
The calibration range for the ELISA method was 0.04 – 25 ng/mL, with a 
reported detection limit of 1-2 pg/well  and a practical linear range in our laboratory of 
0.16 – 2.5 ng/mL. Brain tissue extracts were reconstituted in 500 µL assay buffer to 
generate concentrations on the linear portion of the ELISA calibration curve, and aliquots 
of 50 uL were assayed in duplicate with the mean results reported in Table 4.17. %CV for 
the duplicate measurements was ≤30%. Using this ELISA kit,  mGnRH might be reliably 
measured in tissue samples with as little as 32 pg/tissue (accounting for the practical 
linear range, and duplicate measurements as is customary for ELISA procedures). 
136 
 
 
Results obtained for these comparative samples are presented in Table 4.17. The 
results are shown in Figure 4.10 and were well correlated, with an R2=0.968. The values 
obtained from the LC-MS/MS data were generally higher than those obtained from the 
ELISA assay, as manifested in the regression results as a slope > 1. Without a 
comparative sample in which the actual (nominal) concentration is known, it is difficult 
to make judgements regarding which of these datasets is more accurate. Nonetheless, 
reasonable agreement is demonstrated between the two methods. 
 
 
Table 4.17. Comparison of ELISA and MS  
 
Gender ELISA 
pg/tissue 
LC-MS/MS 
pg/tissue 
|%Difference| 
(calculated relative 
to mean results) 
male 307 368 18.1 
male 545 575 5.36 
male 535 602 11.8 
male 211 279 27.8 
male 295 269 9.22 
female 1040 1310 23.0 
female 285 423 39.0 
female 262 340 25.9 
female 214 303 34.4 
female 225 243 7.69 
    
Mean 392 471  
Std. Dev. 258 320  
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Figure 4.10.  Comparison of mGnRH measured by ELISA and LC-MS/MS 
 
 
 
Sprague-Dawley Rat Brains 
Brains from sixteen male and fifteen female Sprague-Dawley rats were processed 
and analyzed with the validated LC-MS/MS method. Male rats ranged from 8 to 10 
weeks in age, and female rats from 20 to 22 and 26 to 30 weeks. Hyp9GnRH and mGnRH 
were detected in all tissues, as shown in Table 4.18, with consistently lower 
concentrations of Hyp9GnRH than mGnRH. 
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Table 4.18. Concentrations of Hyp9GnRH and mGnRH in male and female 
Sprague-Dawley rat brains  
male  female 
Age 
(weeks) 
Hyp9GnRH 
pg/tissue 
mGnRH 
pg/tissue 
Ratio 
Hyp9/m 
 Age 
(weeks) 
Hyp9GnRH 
pg/tissue 
mGnRH 
pg/tissue 
Ratio 
Hyp9/m 
8-10 271 1320 0.21  26-30 159 1150 0.14 
8-10 168 1100 0.15  26-30 177 1350 0.13 
8-10 333 1820 0.18  26-30 129 692 0.19 
8-10 260 1070 0.24  26-30 74.5 509 0.15 
8-10 291 1280 0.23  26-30 291 1820 0.16 
8-10 244 900 0.27  26-30 169 966 0.18 
8-10 230 1050 0.22  26-30 121 607 0.20 
8-10 277 1370 0.20  26-30 67.2 524 0.13 
8-10 348 1680 0.21  26-30 294 1730 0.17 
8-10 277 1240 0.22  26-30 298 1860 0.16 
8 231 996 0.23  26-30 222 1510 0.15 
8 489 2580 0.19  20-22 255 1560 0.16 
8 348 1840 0.19  20-22 163 798 0.20 
8 198 865 0.23  20-22 231 1290 0.18 
8 515 2480 0.21  20-22 341 1900 0.18 
8 328 1290 0.25      
         
Mean ± 
SEM 301 ± 24 1430 ± 130 0.21 
 Mean ±
SEM 199 ± 22 1220 ± 131 0.16 
Range 168-515 865-2580   Range 67.2-341 509-1900  
Italicized text indicates value lower than the lower limit of quantitation 
 
 
Mean levels of 301 pg/tissue Hyp9GnRH and 1430 pg/tissue mGnRH were 
measured in brains from male rats, and 199 pg/tissue Hyp9GnRH and 1220 pg/tissue 
mGnRH were measured in brains from female rats. Concentrations of Hyp9GnRH were 
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below the lower limit of quantitation in two of the male rat brains and in eight of the 
female rat brains. While accuracy and precision of the assay below 200 pg 
Hyp9GnRH/tissue have not been demonstrated, the ratio of Hyp9GnRH to mGnRH in 
these samples was consistent with the ratios observed for samples where Hyp9GnRH 
values were within the calibration range. All mGnRH determinations were within the 
calibration range of 200-20000 pg/tissue. The mean Hyp9GnRH/mGnRH ratio was 0.21 
in male rats and 0.16 in female rats. 
There are few reports of Hyp9GnRH and mGnRH quantitative measurement in 
individual brain tissues to which these results may be compared. Hypothalamic tissue is 
expected to contain greater than 95% of the Hyp9GnRH and mGnRH present in whole 
brain tissue (7); thus, we expected our measurements to be comparable to those 
previously reported for hypothalamus in the literature. Gautron and colleagues reported 
concentrations in extracts from hypothalami of 500 pg/tissue Hyp9GnRH and 5010 
pg/tissue mGnRH in intact male rats and 251 pg/tissue Hyp9GnRH and 1830 pg/tissue 
mGnRH in intact female rats (age unreported); castration resulted in lower levels for both 
genders, with reported concentrations of 165 pg/tissue Hyp9GnRH and 1380 pg/tissue 
mGnRH in castrated male rats and 113 pg/tissue Hyp9GnRH and 1040 pg/tissue mGnRH 
in female rats (23). Rochdi and colleagues measured mean concentrations of 739 
pg/tissue Hyp9GnRH and 4495 pg/tissue mGnRH in hypothalamic tissues from Sprague-
Dawley rats (age not reported) (9), and found that Hyp9GnRH and mGnRH 
concentrations in hypothalamic tissues increase with age from 2 to 45 days post-natal, 
with the Hyp9GnRH/mGnRH ratio decreasing over that period to approximately 0.15 at 
45 days irrespective of gender (24). All methods measured Hyp9GnRH and mGnRH by 
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separation based on multiple chromatographic methods with fractions collected for 
separate RIA measurements of Hyp9GnRH and mGnRH. 
Mean concentrations of Hyp9GnRH and mGnRH measured in brains from 
Sprague-Dawley rats by LC-MS/MS methodology were somewhat lower than those 
observed in previous studies for intact rats and were similar to those observed for 
castrated rats. The ratio of Hyp9GnRH and mGnRH was consistent with that derived from 
previous observations. GnRH release is known to be pulsatile in nature and inhibited by 
conditions of stress (25-27). Also, the age of animals in our study may differ significantly 
from those utilized in previous studies. These factors make direct comparisons between 
our study and previous work difficult. Nonetheless, our method has been demonstrated to 
have good accuracy and precision, and the values obtained after measurement of 31 male 
and female rat brains are reasonably close to those reported previously in the literature. 
Thus, these results further validate use of the LC-MS/MS method for quantification of 
Hyp9GnRH and mGnRH in samples derived from brain tissue. Strategies to lower the 
calibration range for Hyp9GnRH for future work would be desirable; to this end, 
improved recovery of the GnRH isoforms during extraction and lower detection 
capabilities via nanoflow liquid chromatography could be pursued. 
4.4 CONCLUSIONS 
We have developed and validated an LC-MS/MS method for the simultaneous 
measurement of two GnRH isoforms, Hyp9GnRH and mGnRH, in individual rat brains. 
The method utilizes SPE to isolate GnRH isoforms from the sample followed by a single 
high performance liquid chromatography method interfaced directly with a quadrupole 
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ion trap mass spectrometer. The validated concentration range is 200-20000 pg/tissue for 
both Hyp9GnRH and mGnRH. 
Calibration standards and quality control samples were prepared in halved guinea 
pig brains, which were found to be a suitable substitute blank matrix. Results from the 
validation experiments demonstrated that the method is accurate and precise, with 
suitable stability to allow for analysis of samples up to 24 hours after extraction. 
Furthermore, there was no evidence that Hyp9GnRH or mGnRH were significantly 
degraded in rat brain tissue stored for 112 days at -70ºC. Results from the analysis of 31 
brains from Sprague-Dawley rats using the LC-MS/MS method compare favorably with 
previous studies. To our knowledge, this is the first report of a rigorously validated 
method for measurement of GnRH isoforms in a tissue matrix and the first report of 
simultaneous quantitative measurement of two GnRH isoforms in any biological matrix. 
In addition, this is the first report to assess experimental conditions and long-term storage 
on stability of Hyp9GnRH and mGnRH. 
Replacement of antibody-related detection with LC-MS/MS-based detection of 
Hyp9GnRH and mGnRH has multiple benefits, including improvements in selectivity, 
efficiency, sample throughput, and more precise correction for recovery. Selectivity is 
greatly enhanced because the LC-MS/MS method combines chromatographic separation 
with detection based on a mass/charge ratio rather than on an epitope of the peptide 
structure. The potential for interference from peptide fragments or metabolic products is 
greatly reduced, and additionally, full-scan spectra obtained during the quantitative 
experiment can be assessed for the characteristic fragmentation pattern associated with 
GnRH peptides without consuming additional material in a separate experiment (28). 
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Sample throughput and efficiency are also improved by replacing antibody-based 
detection with the LC-MS/MS method for several reasons. First, because multiple 
isoforms can be measured simultaneously rather than performing immunoassay analysis 
separately for each isoform, only one analysis step is required. Secondly, the 
experimental time with the LC-MS/MS method is greatly reduced compared to 
immunoassay techniques. For the LC-MS/MS analysis, extraction and a complete 
instrument run can be completed within 24 hours; in contrast, RIA procedures alone for 
GnRH analysis can require multi-day incubation steps (7). Furthermore, the LC-MS/MS 
method proved capable of measuring Hyp9GnRH and mGnRH in single rat brain tissues, 
whereas previous studies have utilized large pools of tissue, ranging from tens to 
thousands of hypothalamus and brains (6-8). 
With the LC-MS/MS method, recovery is accounted for within each experiment 
and for every sample due to the use of calibration standards and a structurally-analogous 
internal standard. With the previously-utilized RIA methods, a general recovery factor 
was applied to each individual experiment, requiring the assumption of constant recovery 
from experiment to experiment and sample to sample. While the accuracy and precision 
of RIA methods used for tissue analyses of Hyp9GnRH and mGnRH have not been 
reported, making it difficult to assess how much of an improvement the LC-MS/MS 
method offers over previously-utilized methods, use of internal standard quantitation 
would be expected to improve upon these parameters. 
 In terms of comparison to other similar methods, the data collected for intra- and 
inter-day accuracy and precision during validation of the LC-MS/MS method were within 
the ranges expected for bioanalytical methods of exogenous compounds and compare 
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favorably to reports in the literature for peptide analysis by LC-MS/MS. An LC-MS/MS 
method for EPI-nHE4, a 56-amino acid protein, in plasma samples has been validated 
with reported accuracies of 90.6-106.7%, precision (%RSD) ≤ 13.6, and an LLOQ of 5 
ng/mL (250 pg on-column) (29). A multi-analyte LC-MS/MS assay for tifuvirtide, 
efuvirtide, and a metabolite of efuvirtide in plasma samples has been validated with 
reported accuracies of 87.7-106.9%, precision (%RSD) ≤ 13.4%, and an LLOQ of 20 
ng/mL each peptide (100 pg on-column) (30). The penta-peptide Gluten Exorphin A5 has 
been measured in cerebrospinal fluid by LC-MS with reported accuracies of 99.6-103%, 
precision (%RSD) ≤ 4.99, and an LLOQ of 0.96 ng/mL (160 pg on-column) (31). 
Kahalalide F, a depsipeptide containing 13 amino acids, has been measured in plasma by 
LC-MS/MS with reported accuracies of 84.9-97.3%, precision (%RSD) ≤ 9.91, and an 
LLOQ of 1 ng/mL (12 pg on-column) (32). Finally, an LC-MS method has been 
validated for Cetrorelix, a decapeptide synthesized as a GnRH antagonist and having 
limited structural similarity to mGnRH (50% homology); accuracies of 96.0-114%, 
precision (%RSD) ≤ 13.5, and an LLOQ of 1 ng/mL (400 pg on-column) were reported 
for plasma samples, and accuracies of 86.6-103%, precision (%RSD) ≤ 17.1, and an 
LLOQ of 2 ng/mL (1.7 ng on-column) were reported for urine samples (33). Our LC-
MS/MS method for quantitative measurement of Hyp9GnRH and mGnRH achieved 
accuracies ranging from 94.0-111%, precision (%RSD) ≤ 10.8%, and an LLOQ of 200 
pg/tissue (~50 pg on-column); these measures compare favorably with the data reported 
for bioanalysis of other peptides as described above. 
The calibration range as validated, with a lower limit of quantitation of 200 
pg/tissue, did not encompass the lowest concentrations of Hyp9GnRH measured in rat 
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brain samples; approximately a third of the brains sampled in this study contained 
concentrations of Hyp9GnRH lower than 200 pg/tissue. These results suggest that a 
slightly lower limit of quantitation for Hyp9GnRH should be pursued as a method 
improvement for assay of rat brain samples. Sample reconstitution volumes could be 
halved while maintaining the HPLC injection volume; theoretically, this method change 
could be used to lower the lower limit of quantitation by a factor of 2, to 100 pg/tissue. 
Improved recoveries of GnRH from extracted tissue would also assist in decreasing the 
LLOQ. In combination, these method changes would be expected to reduce the LLOQ 
such that the lower concentrations of Hyp9GnRH in rat brain would be within the 
calibration curve range. For samples where substantially lower concentrations of GnRH 
are expected, conversion of the HPLC method from a microbore column (in this case, 1.0 
mm diameter column) to capillary chromatography (<0.5 mm diameter column) or 
transfer of the method to a newer mass spectrometry platform such as the linear ion trap 
would provide a means to substantially decrease the LLOQ of the method. 
The LC-MS/MS method described here could be extended to other species than 
rat, and the results presented here suggest that guinea pig brain may be a suitable tissue 
matrix for many mammalian species. Adaptation of the LC-MS/MS method to other 
GnRH isoforms should be straightforward, so long as synthetic peptides for use in 
calibration standards and for analogous internal standards are available. The ease with 
which peptides are routinely synthesized means that this methodology can be adapted to 
virtually any GnRH isoform. Extension of the method to other matrices such as blood and 
serum should be feasible as well. 
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We have demonstrated that simultaneous quantitation of two GnRH isoforms with 
good accuracy and precision can be achieved via a new LC-MS/MS method. The new 
method offers substantial improvements over previously utilized immunoassay-based 
methods, including increased specificity, efficiency, and recovery-corrected values. 
Accuracy and precision were difficult to compare to previous GnRH methods, as metrics 
for these parameters have not been reported; however, the new LC-MS/MS method 
compared favorably with other LC-MS and LC-MS/MS methods validated for peptide 
quantitation with regards to accuracy, precision, and limits of quantitation. Future 
applications of the method include continued exploration of the precise function of 
Hyp9GnRH and mGnRH in the rat animal model or investigations of up- or down-
regulation of Hyp9GnRH and mGnRH release after administration of GnRH agonist- or 
antagonist-compounds. For both of these applications, accurate and precise methods of 
quantitation of Hyp9GnRH and mGnRH will be essential. Additionally, it is expected that 
this method could be used as a guide to validate LC-MS/MS methods for quantitative 
measurement of Hyp9GnRH or mGnRH in species other than rat or extended to 
measurement of other GnRH isoforms with relative ease. 
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5CHAPTER 5: SUMMARY 
 
Gonadotropin-releasing hormones (GnRH) have been found in a wide diversity of 
species. Twenty four isoforms have been characterized thus far in vertebrate and 
invertebrate species, and it is likely that additional isoforms will be discovered. This 
dissertation describes the investigation of reversed-phase chromatographic and mass 
spectrometric behavior of GnRH peptides, the development and application of an LC-
MS/MS method for qualitative identification of GnRH peptides, and the comprehensive 
validation of an LC-MS/MS method for simultaneous, quantitative measurement of 
hydroxyproline9GnRH (Hyp9GnRH) and mammalian GnRH (mGnRH) in rat brain 
tissues. The LC-MS/MS-based qualitative and quantitative methods described in this 
dissertation provide alternatives to the antibody-based detection techniques that have 
been the predominant techniques for GnRH characterization and measurement, with the 
advantages of these new LC-MS/MS methods described below. 
 Chapter 2 describes the chromatographic and mass spectrometric behavior of a 
model set of six GnRH peptides, chicken I GnRH, chicken II GnRH, lamprey III GnRH, 
mGnRH, salmon GnRH and seabream GnRH. Mobile phase composition and reversed-
phase column composition were explored to optimize chromatography, and effects of 
solution composition and electrospray parameters on signal intensity and peptide charge 
states were investigated. Nearly complete separation of the six model peptides was 
achieved using gradient reversed phase chromatography with a 50 x 1.0 mm C8 
chromatography column, and mobile phases prepared with acetic acid were found to 
provide optimized response. The capillary temperature setting for the electrospray source 
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was found to affect the charge state distribution for GnRH peptides having more than one 
main charge state, offering a mechanism to “tune” the electrospray settings for a 
particular charge state. The electrospray source voltage setting was found to have an 
optimal range for the six GnRH peptides. These results were used to develop the 
qualitative LC-MS/MS method presented in Chapter 3, which was developed as a 
generalized approach to facilitate identification of any isoform in the GnRH peptide 
group, and the quantitative LC-MS/MS method described in Chapter 4. 
In Chapter 3, the development and application of an LC-MS/MS method capable of 
simultaneous separation and identification of multiple GnRH isoforms is described. 
MS/MS fragmentation patterns observed from the model set of six GnRH isoforms were 
used to define characteristic transitions and marker ions for the family of peptides and to 
ensure that the proline in position 9 would not dominate fragmentation and prevent 
obtaining an adequate series of ions for de novo sequencing. A simple solid phase 
extraction procedure was developed to prepare rat brain homogenates for LC-MS/MS 
analysis. To investigate feasibility, six model GnRH peptides were used to prepare a 
control sample from Sprague-Dawley rat brain for data-dependent experiments; results 
indicated that sufficient sequencing information could be obtained to identify all six 
GnRH peptide structures by de novo sequencing. In an unspiked pool of ten Sprague-
Dawley rat brains, two putative GnRH peptides were detected with molecular weights 
and fragmentation patterns consistent with what would be expected from Hyp9GnRH and 
mGnRH. An extract containing these natural peptides was augmented with synthetic 
Hyp9GnRH and mGnRH peptide standards, demonstrating coelution of the synthetic and 
natural peptides and similarity of MS/MS fragmentation patterns; these results confirmed 
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the identify of Hyp9GnRH and mGnRH in extracts from Sprague-Dawley rat brains. The 
LC-MS/MS method described in this chapter was able to provide qualitative information 
with as little as 10 pg peptide for detection of GnRH peptides of known sequence or 300-
500 pg peptide for detection and sequencing of novel GnRH isoforms. Targeted product-
ion analysis experiments were conducted in pooled extract from rat brains to search for 
GnRH isoforms that have been previously reported – chicken II GnRH, lamprey III 
GnRH, and salmon GnRH. No evidence supporting the expression of any of these 
isoforms was found. These results support the hypothesis that mGnRH and its post-
translationally modified form, Hyp9GnRH, are the primary, if not only, forms of GnRH 
expressed in rat brains. 
Chapter 4 describes the comprehensive validation of an LC-MS/MS method for 
simultaneous quantitative measurement of Hyp9GnRH and mGnRH in rat brain samples. 
Calibration standards and quality control samples were prepared in guinea pig brains, 
which were found to be a suitable blank matrix for the assay. A simple solid phase 
extraction procedure was employed prior to LC-MS/MS analysis. Internal standard 
quantitation was performed with an analogue to mGnRH, and the validated concentration 
range was 200 - 20000 pg for each peptide. For both Hyp9GnRH and mGnRH, the intra- 
and inter-run accuracy and precision measures were good. Sufficient stability at room 
temperature, during freeze/thaw cycles, after extraction and under long-term storage 
conditions were found to accommodate typical laboratory procedures. Comparison of 
mGnRH quantitation using the LC-MS/MS assay to a commercially available ELISA kit 
produced reasonable agreement between the two methods. Thirty-one brains from 
Sprague-Dawley rats were analyzed using the LC-MS/MS procedure and compared to 
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published results for Hyp9GnRH and mGnRH. The validated LC-MS/MS method offers 
numerous improvements to preceding methods for Hyp9GnRH and mGnRH 
measurement in tissue samples. Replacement of antibody-based detection with detection 
based on a mass/charge ratio improved selectivity, efficiency and sample throughput as 
compared to previously reported methods; also, the inclusion of extracted calibration 
standards and internal standard quantitation allowed for a more precise accounting of 
recovery within each experiment and for each sample. The method should be easily 
adaptable to the measurement of other GnRH isoforms. To our knowledge, this is the first 
report of a rigorously validated method for measurement of GnRH isoforms in a tissue 
matrix and the first report of simultaneous quantitative measurement of two GnRH 
isoforms in any biological matrix. In addition, these experiments provide the first 
reported assessment of experimental conditions and long-term storage on stability of 
Hyp9GnRH and mGnRH. 
